Departement
Klinische Forschung
Achtung: Diese Seite kann nur von Administratoren besucht werden, da Sie nicht freigeschalten wurde.
Zurück
Publications Battegay Manuel E.

[HIV in Sub-Saharan Africa: Where Are We Today?]

Eichenberger A; Weisser M; Battegay M. Praxis. 2019.

Age-related comorbidities and mortality in people living with HIV in rural Tanzania.

Albrecht S; Franzeck FC; Mapesi H; Hatz C; Kalinjuma AV; Glass TR; Mnzava D; Letang E; Paris DH; Battegay M; Weisser M; KIULARCO Study Group.. AIDS (London, England). 2019.

A Systematic Phylogenetic Approach to Study the Interaction of HIV-1 With Coinfections, Noncommunicable Diseases, and Opportunistic Diseases.

Kusejko K; Bachmann N; Chaudron SE; Nguyen H; Braun DL; Hampel B; Battegay M; Bernasconi E; Calmy A; Cavassini M; Hoffmann M; Böni J; Yerly S; Klimkait T; Perreau M; Rauch A; Günthard HF; Kouyos RD; Swiss HIV Cohort Study.. The Journal of infectious diseases. 2019.

Cost estimates for Human Immunodeficiency Virus (HIV) care and patient characteristics for health resource use from linkage of claims data with the swiss HIV cohort study

Leon-Reyes S.; Schafer J.; Fruh M.; Schwenkglenks M.; Reich O.; Schmidlin K.; Staehelin C.; Battegay M.; Cavassini M.; Hasse B.; Bernasconi E.; Calmy A.; Hoffmann M.; Schoeni-Affolter F.; Zhao H.; Bucher H.C.. Clinical Infectious Diseases. 2019.

Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART.

Bachmann N; von Siebenthal C; Vongrad V; Turk T; Neumann K; Beerenwinkel N; Bogojeska J; Fellay J; Roth V; Kok YL; Thorball CW; Borghesi A; Parbhoo S; Wieser M; Böni J; Perreau M; Klimkait T; Yerly S; Battegay M; Rauch A; Hoffmann M; Bernasconi E; Cavassini M; Kouyos RD; Günthard HF; Metzner KJ; Swiss HIV Cohort Study.. Nature Communications. 2019.

Frequent Door Openings During Cardiac Surgery Are Associated With Increased Risk for Surgical Site Infection: A Prospective Observational Study.

Roth JA; Juchler F; Dangel M; Eckstein FS; Battegay M; Widmer AF. Clinical Infectious Diseases. 2019.

High Mortality of Non-Fournier Necrotizing Fasciitis With Enterobacteriales: Time to Rethink Classification?

Kuehl R; Tschudin-Sutter S; Siegemund M; Marsch S; Battegay M; Wetterauer C; Seifert HH; Schaefer DJ; Erb S; Egli A. Clinical Infectious Diseases. 2019.

HIV Transmission Chains Exhibit Greater HLA-B Homogeneity Than Randomly Expected.

Nguyen H; Thorball CW; Fellay J; Böni J; Yerly S; Perreau M; Klimkait T; Kusejko K; Bachmann N; Chaudron SE; Paioni P; Thurnheer MC; Battegay M; Cavassini M; Vernazza P; Bernasconi E; Günthard HF; Kouyos R; Swiss HIV Cohort Study.. Journal of Acquired Immune Deficiency Syndromes. 2019.

Identification of influenza urban transmission patterns by geographical, epidemiological and whole genome sequencing data: protocol for an observational study.

Egli A; Saalfrank C; Goldman N; Brunner M; Hollenstein Y; Vogel T; Augustin N; Wüthrich D; Seth-Smith HMB; Roth E; Syedbasha M; Mueller NF; Vogt D; Bauer J; Amar-Sliwa N; Meinel DM; Dubuis O; Naegele M; Tschudin-Sutter S; Buser A; Nickel CH; Zeller A; Ritz N; Battegay M; Stadler T; Schneider-Sliwa R. BMJ Open. 2019.

Impact of health insurance status on surgical site infection incidence: A prospective cohort study.

Duggan BT; Roth JA; Dangel M; Battegay M; Widmer AF. Infection control and hospital epidemiology. 2019.

Plea for Standardized Reporting and Justification of Propensity Score Methods.

Roth JA; Juchler F; Widmer AF; Battegay M. Clinical Infectious Diseases. 2019.

Polypharmacy, drug–drug interactions, and inappropriate drugs: New challenges in the aging population with HIV

Courlet P.; Livio F.; Guidi M.; Cavassini M.; Battegay M.; Stoeckle M.; Buclin T.; Saldanha S.A.; Csajka C.; Marzolini C.; Decosterd L.; Anagnostopoulos A.; Battegay M.; Bernasconi E.; Boni J.; Braun D.L.; Bucher H.C.; Calmy A.; Cavassini M.; Ciuffi A.; Dollenmaier G.; Egger M.; Elzi L.; Fehr J.; Fellay J.; Furrer H.; Fux C.A.; Gunthard H.F.; Haerry D.; Hasse B.; Hirsch H.H.; Hoffmann M.; Hosli I.; Huber M.; Kahlert C.R.; Kaiser L.; Keiser O.; Klimkait T.; Kouyos R.D.; Kovari H.; Ledergerber B.; Martinetti G.; Martinez De Tejada B.; Marzolini C.; Metzner K.J.; Muller N.; Nicca D.; Paioni P.; Pantaleo G.; Perreau M.; Rauch A.; Rudin C.; Scherrer A.U.; Schmid P.; Speck R.; Stockle M.; Tarr P.; Trkola A.; Vernazza P.; Wandeler G.; Weber R.; Yerly S.. Open Forum Infectious Diseases. 2019.

Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes.

Stader F; Siccardi M; Battegay M; Kinvig H; Penny MA; Marzolini C. CLINICAL PHARMACOKINETICS. 2019.

Safety and tolerance of lymph node biopsies from chronic HIV-1 volunteers in rural Tanzania

Mkindi C.G.; Marandu E.A.; Masawa N.; Bani F.; Nyuri A.; Byakuzana T.; Klimkait T.; Ding S.; Pantaleo G.; Battegay M.; Orlova-Fink N.; Weisser-Rohacek M.; Daubenberger C.. BMC research notes. 2019.

Screening HIV-positive men who have sex with men for hepatitis C re-infection risk: is a single question on condom-use enough? A sensitivity analysis.

Künzler-Heule P; Engberg S; Battegay M; Schmidt AJ; Fierz K; Nguyen H; Kocher A; Nöstlinger C; Hampel B; Stöckle M; Béguelin C; Delaloye J; Schmid P; Flepp M; Rougement M; Braun DL; Fehr J; Nicca D; Swiss HIV Cohort Study (SHCS).. BMC INFECTIOUS DISEASES. 2019.

Sonography to Rule Out Tuberculosis in Sub-Saharan Africa: A Prospective Observational Study.

Ndege R; Weisser M; Elzi L; Diggelmann F; Bani F; Gingo W; Sikalengo G; Mapesi H; Mchomvu E; Kamwela L; Mnzava D; Battegay M; Reither K; Paris DH; Rohacek M. Open Forum Infectious Diseases. 2019.

The HOSENG trial - Effect of the provision of oral self-testing for absent and refusing individuals during a door-to-door HIV-testing campaign on testing coverage: protocol of a cluster-randomized clinical trial in rural Lesotho.

Amstutz A; Lejone TI; Khesa L; Muhairwe J; Nsakala BL; Tlali K; Bresser M; Vanobberghen F; Kopo M; Kao M; Klimkait T; Battegay M; Labhardt ND; Glass TR. Trials. 2019.

The rate of mother-to-child transmission of antiretroviral drug-resistant HIV strains is low in the Swiss Mother and Child HIV Cohort Study.

Compagno F; Naegele K; Kahlert CR; Hösli I; Aebi-Popp K; Martinez de Tejada B; Paioni P; Yerly S; Böni J; Battegay M; Rudin C; Hirsch HH; Swiss Hiv Cohort Study. Swiss medical weekly. 2019.

VIBRA trial - Effect of village-based refill of ART following home-based same-day ART initiation vs clinic-based ART refill on viral suppression among individuals living with HIV: protocol of a cluster-randomized clinical trial in rural Lesotho.

Amstutz A; Lejone TI; Khesa L; Muhairwe J; Nsakala BL; Tlali K; Bresser M; Tediosi F; Kopo M; Kao M; Klimkait T; Battegay M; Glass TR; Labhardt ND. Trials. 2019.

Viral Diversity Based on Next-Generation Sequencing of HIV-1 Provides Precise Estimates of Infection Recency and Time Since Infection.

Carlisle LA; Turk T; Kusejko K; Metzner KJ; Leemann C; Schenkel CD; Bachmann N; Posada S; Beerenwinkel N; Böni J; Yerly S; Klimkait T; Perreau M; Braun DL; Rauch A; Calmy A; Cavassini M; Battegay M; Vernazza P; Bernasconi E; Günthard HF; Kouyos RD; Swiss HIV Cohort Study.. The Journal of infectious diseases. 2019.

Why do sub-Saharan Africans present late for HIV care in Switzerland?

Hachfeld A.; Darling K.; Calmy A.; Ledergerber B.; Weber R.; Battegay M.; Wissel K.; Di Benedetto C.; Fux C.A.; Tarr P.E.; Kouyos R.D.; Ruggia L.S.; Furrer H.J.; Wandeler G.; Aubert V.; Battegay M.; Bernasconi E.; Boni J.; Braun D.L.; Bucher H.C.; Calmy A.; Cavassini M.; Ciuffi A.; Dollenmaier G.; Egger M.; Elzi L.; Fehr J.; Fellay J.; Furrer H.; Fux C.A.; Gunthard H.F.; Haerry D.; Hasse B.; Hirsch H.H.; Hoffmann M.; Hosli I.; Kahlert C.; Kaiser L.; Keiser O.; Klimkait T.; Kouyos R.D.; Kovari H.; Ledergerber B.; Martinetti G.; Martinez de Tejada B.; Marzolini C.; Metzner K.J.; Muller N.; Nicca D.; Pantaleo G.; Paioni P.; Rauch A.; Rudin C.; Scherrer A.U.; Schmid P.; Speck R.; Stockle M.; Tarr P.; Trkola A.; Vernazza P.; Wandeler G.; Weber R.; Yerly S.. HIV medicine. 2019.

Aids in Basel - Vom Sterben an Aids zum Leben mit HIV

Goetz U; Hicklin M; Battegay M. . 2018.

Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications.

Stader F; Kinvig H; Battegay M; Khoo S; Owen A; Siccardi M; Marzolini C. Antimicrobial agents and chemotherapy. 2018.

Boosted darunavir, emtricitabine and tenofovir pharmacokinetics in sthe early and late postgastric bypass surgery periods.

Baettig V; Courlet P; Delko T; Battegay M; Marzolini C. AIDS (London, England). 2018.

Brief Report: No HIV Transmission From Virally Suppressed Mothers During Breastfeeding in Rural Tanzania.

Luoga E; Vanobberghen F; Bircher R; Nyuri A; Ntamatungiro AJ; Mnzava D; Mollel GJ; Letang E; Battegay M; Weisser M; Gamell A. Journal of Acquired Immune Deficiency Syndromes. 2018.

Costs versus earnings in colon surgery and coronary artery bypass grafting under a prospective payment system: Sufficient financial incentives to reduce surgical site infections?

Juchler F; Roth JA; Schweiger A; Dangel M; Gugliotta M; Battegay M; Eckstein FS; Kettelhack C; Abshagen C; Hug BL; Boyce JM; Widmer AF. Infection control and hospital epidemiology. 2018.

Die virale Arthritis beim Erwachsenen

Sendi P; Kuehl R; Labhardt N; Battegay M; Aeberli D. . 2018.

Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma.

Shepherd L; Ryom L; Law M; Hatleberg CI; de Wit S; Monforte AD; Battegay M; Phillips A; Bonnet F; Reiss P; Pradier C; Grulich A; Sabin C; Lundgren J; Mocroft A. JNCI-Journal of the National Cancer Institute. 2018.

Digging Out the Evidence-How Strong Is the IDSA Recommendation Against Antibiotic Prophylaxis in Basilar Skull Fracture and Cerebrospinal Fluid Leakage?

Kuehl R; Büchler A; Widmer AF; Battegay M. Clinical Infectious Diseases. 2018.

Direct Costs of a Contact Isolation Day: A Prospective Cost Analysis at a Swiss University Hospital.

Roth JA; Hornung-Winter C; Radicke I; Hug BL; Biedert M; Abshagen C; Battegay M; Widmer AF. Infection control and hospital epidemiology. 2018.

Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity.

Bertels F; Marzel A; Leventhal G; Mitov V; Fellay J; Günthard HF; Böni J; Yerly S; Klimkait T; Aubert V; Battegay M; Rauch A; Cavassini M; Calmy A; Bernasconi E; Schmid P; Scherrer AU; Müller V; Bonhoeffer S; Kouyos R; Regoes RR; Swiss HIV Cohort Study.. MOLECULAR BIOLOGY AND EVOLUTION. 2018.

Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity.

Kadelka C; Liechti T; Ebner H; Schanz M; Rusert P; Friedrich N; Stiegeler E; Braun DL; Huber M; Scherrer AU; Weber J; Uhr T; Kuster H; Misselwitz B; Cavassini M; Bernasconi E; Hoffmann M; Calmy A; Battegay M; Rauch A; Yerly S; Aubert V; Klimkait T; Böni J; Kouyos RD; Günthard HF; Trkola A; Swiss HIV Cohort Study.. The Journal of experimental medicine. 2018.

European AIDS Clinical Society Second Standard of Care Meeting, Brussels 16-17 November 2016: a summary.

De Wit S; Battegay M; D'Arminio Monforte A; Lundgren JD; Oprea C; Antinori A; Bhagani S; Fätkenheuer G; Friis-Moller N; Furrer H; Mussini C; European AIDS Clinical Society.. HIV medicine. 2018.

Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0.

Ryom L; Boesecke C; Bracchi M; Ambrosioni J; Pozniak A; Arribas J; Behrens G; Mallon P; Puoti M; Rauch A; Miro JM; Kirk O; Marzolini C; Lundgren JD; Battegay M; EACS Governing Board.. HIV medicine. 2018.

Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study.

Kusejko K; Kadelka C; Marzel A; Battegay M; Bernasconi E; Calmy A; Cavassini M; Hoffmann M; Böni J; Yerly S; Klimkait T; Perreau M; Rauch A; Günthard HF; Kouyos RD; Swiss HIV Cohort Study .. Virus evolution. 2018.

Introduction to Machine Learning in Digital Healthcare Epidemiology.

Roth JA; Battegay M; Juchler F; Vogt JE; Widmer AF. Infection control and hospital epidemiology. 2018.

Lipodystrophy Increases the Risk of CKD Development in HIV-Positive Patients in Switzerland: The LIPOKID Study.

Bouatou Y; Gayet Ageron A; Bernasconi E; Battegay M; Hoffmann M; Staehelin C; Merz L; Kovari H; Fux C; de Seigneux S; Calmy A; Swiss HIV Cohort Study.. Kidney International Reports. 2018.

Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals.

Conconi A; Zucca E; Margiotta-Casaluci G; Darling K; Hasse B; Battegay M; Staehelin C; Novak U; Schmid P; Scherrer A; Dirnhofer S; Kwee I; Nassi L; Cavalli F; Gaidano G; Bertoni F; Bernasconi E; Swiss HIV Cohort study (SHCS).. Hematological oncology. 2018.

Prevalence and Evolution of Renal Impairment in People Living With HIV in Rural Tanzania.

Mapesi H; Kalinjuma AV; Ngerecha A; Franzeck F; Hatz C; Tanner M; Mayr M; Furrer H; Battegay M; Letang E; Weisser M; Glass TR; KIULARCO Study Group .. Open Forum Infectious Diseases. 2018.

Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland.

Kusejko K; Marzel A; Hampel B; Bachmann N; Nguyen H; Fehr J; Braun DL; Battegay M; Bernasconi E; Calmy A; Cavassini M; Hoffmann M; Böni J; Yerly S; Klimkait T; Perreau M; Rauch A; Günthard HF; Kouyos RD; Swiss HIV Cohort Study.. HIV medicine. 2018.

SESOTHO trial ("Switch Either near Suppression Or THOusand") - switch to second-line versus WHO-guided standard of care for unsuppressed patients on first-line ART with viremia below 1000 copies/mL: protocol of a multicenter, parallel-group, open-label, randomized clinical trial in Lesotho, Southern Africa.

Amstutz A; Nsakala BL; Vanobberghen F; Muhairwe J; Glass TR; Achieng B; Sepeka M; Tlali K; Sao L; Thin K; Klimkait T; Battegay M; Labhardt ND. BMC Infectious Diseases. 2018.

Tracing HIV-1 strains that imprint broadly neutralizing antibody responses.

Kouyos RD; Rusert P; Kadelka C; Huber M; Marzel A; Ebner H; Schanz M; Liechti T; Friedrich N; Braun DL; Scherrer AU; Weber J; Uhr T; Baumann NS; Leemann C; Kuster H; Chave JP; Cavassini M; Bernasconi E; Hoffmann M; Calmy A; Battegay M; Rauch A; Yerly S; Aubert V; Klimkait T; Böni J; Metzner KJ; Günthard HF; Trkola A; Swiss HIV Cohort Study.. Nature. 2018.

Using dried blood spots to facilitate therapeutic drug monitoring of antiretroviral drugs in resource-poor regions.

Duthaler U; Berger B; Erb S; Battegay M; Letang E; Gaugler S; Natamatungiro A; Mnzava D; Donzelli M; Krähenbühl S; Haschke M. Journal of Antimicrobial Chemotherapy. 2018.

A decade of HIV care in rural Tanzania: Trends in clinical outcomes and impact of clinic optimisation in an open, prospective cohort.

Vanobberghen F; Letang E; Gamell A; Mnzava DK; Faini D; Luwanda LB; Mapesi H; Mwamelo K; Sikalengo G; Tanner M; Hatz C; Furrer H; Battegay M; Glass TR; KIULARCO Study Group.. PLoS One. 2017.

Adverse events of raltegravir and dolutegravir.

Elzi L; Erb S; Furrer H; Cavassini M; Calmy A; Vernazza P; Günthard H; Bernasconi E; Battegay M; Swiss HIV Cohort Study Group.. AIDS (London, England). 2017.

Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis.

Turk T; Bachmann N; Kadelka C; Böni J; Yerly S; Aubert V; Klimkait T; Battegay M; Bernasconi E; Calmy A; Cavassini M; Furrer H; Hoffmann M; Günthard HF; Kouyos RD; Swiss HIV Cohort Study.; Aubert V; Battegay M; Bernasconi E; Böni J; Braun DL; Bucher HC; Calmy A; Cavassini M; Ciuffi A; Dollenmaier G; Egger M; Elzi L; Fehr J; Fellay J; Furrer H; Fux CA; Günthard HF; Haerry D; Hasse B; Hirsch HH; Hoffmann M; Hösli I; Kahlert C; Kaiser L; Keiser O; Klimkait T; Kouyos RD; Kovari H; Ledergerber B; Martinetti G; Martinez de Tejada B; Marzolini C; Metzner KJ; Müller N; Nicca D; Pantaleo G; Paioni P; Rauch A; Rudin C; Scherrer AU; Schmid P; Speck R; Stöckle M; Tarr P; Trkola A; Vernazza P; Wandeler G; Weber R; Yerly S. Elife. 2017.

Association of daptomycin use with resistance development in Enterococcus faecium bacteraemia-a 7-year individual and population-based analysis.

Egli A; Schmid H; Kuenzli E; Widmer AF; Battegay M; Plagge H; Frei R; Achermann R; Weisser M. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2017.

Automated high throughput analysis of antiretroviral drugs in dried blood spots.

Duthaler U; Berger B; Erb S; Battegay M; Letang E; Gaugler S; Krähenbühl S; Haschke M. JOURNAL OF MASS SPECTROMETRY. 2017.

Cohort profile: The Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) - A prospective HIV cohort in rural Tanzania.

Letang E; Kalinjuma AV; Glass TR; Gamell A; Mapesi H; Sikalengo GR; Luwanda LB; Mnzava D; Ntamatungiro AJ; Ndaki R; Francis G; Vanobberghen F; Furrer H; Klimkait T; Felger I; Tanner M; Hatz C; Weisser M; Battegay M; Kiularco Study Group. Swiss medical weekly. 2017.

Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.

Bartels H; Decosterd L; Battegay M; Marzolini C. Journal of Antimicrobial Chemotherapy. 2017.

Development of HIV drug resistance and therapeutic failure in children and adolescents in rural Tanzania: an emerging public health concern.

Muri L; Gamell A; Ntamatungiro AJ; Glass TR; Luwanda LB; Battegay M; Furrer H; Hatz C; Tanner M; Felger I; Klimkait T; Letang E; KIULARCO Study Group.. AIDS (London, England). 2017.

Dolutegravir plasma levels after gastric bypass surgery.

Piso RJ; Battegay M; Marzolini C. AIDS (London, England). 2017.

Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals.

Shilaih M; Marzel A; Braun DL; Scherrer AU; Kovari H; Young J; Calmy A; Darling K; Battegay M; Hoffmann M; Bernasconi E; Thurnheer MC; Günthard HF; Kouyos RD; and the Swiss HIV Cohort Study.. Medicine. 2017.

Health care provider communication training in rural Tanzania empowers HIV-infected patients on antiretroviral therapy to discuss adherence problems.

Erb S; Letang E; Glass TR; Natamatungiro A; Mnzava D; Mapesi H; Haschke M; Duthaler U; Berger B; Muri L; Bader J; Marzolini C; Elzi L; Klimkait T; Langewitz W; Battegay M; Kilombero Ulanga Antiretroviral Cohort (KIULARCO) study group.. HIV medicine. 2017.

Hepatitis delta-associated mortality in HIV/HBV-coinfected patients.

Béguelin C; Moradpour D; Sahli R; Suter-Riniker F; Lüthi A; Cavassini M; Günthard HF; Battegay M; Bernasconi E; Schmid P; Calmy A; Braun DL; Furrer H; Rauch A; Wandeler G; Swiss HIV Cohort Study.. Journal of hepatology. 2017.

Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study.

Béguelin C; Friolet N; Moradpour D; Sahli R; Suter-Riniker F; Lüthi A; Cavassini M; Günthard HF; Battegay M; Bernasconi E; Schmid P; Calmy A; Atkinson A; Rauch A; Wandeler G; Swiss HIV Cohort Study.. Clinical Infectious Diseases. 2017.

Incidence and risk factors for hypertension among HIV patients in rural Tanzania - A prospective cohort study.

Rodríguez-Arbolí E; Mwamelo K; Kalinjuma AV; Furrer H; Hatz C; Tanner M; Battegay M; Letang E; KIULARCO Study Group.. PLoS One. 2017.

Increasing prevalence of infectious diseases in asylum seekers at a tertiary care hospital in Switzerland.

Bloch-Infanger C; Bättig V; Kremo J; Widmer AF; Egli A; Bingisser R; Battegay M; Erb S. PLoS One. 2017.

Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population.

Gueler A; Moser A; Calmy A; Günthard HF; Bernasconi E; Furrer H; Fux CA; Battegay M; Cavassini M; Vernazza P; Zwahlen M; Egger M; Swiss HIV Cohort Study, Swiss National Cohort.. AIDS (London, England). 2017.

Mining for pairs: shared clinic visit dates identify steady HIV-positive partnerships.

Marzel A; Shilaih M; Turk T; Campbell NK; Yang WL; Böni J; Yerly S; Klimkait T; Aubert V; Furrer H; Calmy A; Battegay M; Cavassini M; Bernasconi E; Schmid P; Metzner KJ; Günthard HF; Kouyos RD; Swiss HIV Cohort Study (SHCS).. HIV medicine. 2017.

Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.

Marzolini C; Rajoli R; Battegay M; Elzi L; Back D; Siccardi M. CLINICAL PHARMACOKINETICS. 2017.

Prevention of mother-to-child transmission of HIV Option B+ cascade in rural Tanzania: The One Stop Clinic model.

Gamell A; Luwanda LB; Kalinjuma AV; Samson L; Ntamatungiro AJ; Weisser M; Gingo W; Tanner M; Hatz C; Letang E; Battegay M; KIULARCO Study Group.. PLoS One. 2017.

Previous exposure in a high-risk area for travellers' diarrhoea within the past year is associated with a significant protective effect for travellers' diarrhoea: a prospective observational cohort study in travellers to South Asia.

Kuenzli E; Juergensen D; Kling K; Jaeger VK; DeCrom S; Steffen R; Widmer AF; Battegay M; Hatz C; Neumayr A. Journal of travel medicine. 2017.

Reference curves for CD4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-naïve patients.

Bouteloup V; Sabin C; Mocroft A; Gras L; Pantazis N; Le Moing V; d'Arminio Monforte A; Mary-Krause M; Roca B; Miro JM; Battegay M; Brockmeyer N; Berenguer J; Morlat P; Obel N; De Wit S; Fätkenheuer G; Zangerle R; Ghosn J; Pérez-Hoyos S; Campbell M; Prins M; Chêne G; Meyer L; Dorrucci M; Torti C; Thiébaut R; Standard Reference Distribution of CD4 Response to HAART Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.. HIV medicine. 2017.

Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.

Sculier D; Gayet-Ageron A; Battegay M; Cavassini M; Fehr J; Hirzel C; Schmid P; Bernasconi E; Calmy A; Swiss HIV Cohort Study.. BMC Infectious Diseases. 2017.

Specificity of two HIV screening tests detecting simultaneously HIV-1 p24 antigen and antibodies to HIV-1 and −2

Blaich A.; Buser A.; Stockle M.; Gehringer C.; Hirsch H.H.; Battegay M.; Klimkait T.; Frei R.. JOURNAL OF VIROLOGICAL METHODS. 2017.

Strengthening HIV therapy and care in rural Tanzania affects rates of viral suppression

Ntamatungiro A.J.; Muri L.; Glass T.R.; Erb S.; Battegay M.; Furrer H.; Hatz C.; Tanner M.; Felger I.; Klimkait T.; Letang E.; Asantiel A.; Chale A.; Faini D.; Francis G.; Gamell A.; Hwaya S.; Kalinjuma A.V.; Kasuga B.; Kimera N.; Kisunga Y.; Luhombero A.; Luwanda L.B.; Mapesi H.; Mbwile L.; Mkulila M.; Mkumbo J.; Mkusa M.; Mnzava D.K.; Mossad G.; Mpundunga D.; Msami D.; Mtandanguo A.; Mwamelo K.D.; Myeya S.; Nahota S.; Ndaki R.; Ngulukila A.; Samson L.; Sikalengo G.; Vanobberghen F.; Weisser M.. Journal of Antimicrobial Chemotherapy. 2017.

The Model for End-stage Liver Disease (MELD) as a predictor of short-term mortality in Staphylococcus aureus bloodstream infection: A single-centre observational study.

Roth JA; Widmer AF; Tschudin-Sutter S; Dangel M; Frei R; Battegay M; Hug BL. PLoS One. 2017.

Value of the Pitt Bacteraemia Score to predict short-term mortality in Staphylococcus aureus bloodstream infection: a validation study.

Roth JA; Tschudin-Sutter S; Dangel M; Frei R; Battegay M; Widmer AF. Schweizerische Medizinische Wochenschrift. 2017.

[57-year-old patient with unclear cutaneous finding].

Schleenvoigt BT; Bloch-Infanger C; Pletz MW; Hasenböhler P; Battegay M. Deutsche medizinische Wochenschrift (1946). 2016.

CD4/CD8 ratio and CD8 counts predict CD4 response in HIV-1-infected drug naive and in patients on cART.

Sauter R; Huang R; Ledergerber B; Battegay M; Bernasconi E; Cavassini M; Furrer H; Hoffmann M; Rougemont M; Günthard HF; Held L; and the Swiss HIV cohort study.. Medicine. 2016.

Determinants of HIV-1 broadly neutralizing antibody induction.

Rusert P; Kouyos RD; Kadelka C; Ebner H; Schanz M; Huber M; Braun DL; Hozé N; Scherrer A; Magnus C; Weber J; Uhr T; Cippa V; Thorball CW; Kuster H; Cavassini M; Bernasconi E; Hoffmann M; Calmy A; Battegay M; Rauch A; Yerly S; Aubert V; Klimkait T; Böni J; Fellay J; Regoes RR; Günthard HF; Trkola A; Swiss HIV Cohort Study.. Nature medicine. 2016.

Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis.

Shilaih M; Marzel A; Scherrer AU; Braun DL; Kovari H; Rougemont M; Darling K; Battegay M; Hoffmann M; Bernasconi E; Hirzel C; Günthard HF; Kouyos RD; Swiss HIV Cohort Study a.; Swiss HIV Cohort Study.. The Journal of infectious diseases. 2016.

Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis.

Shilaih M; Marzel A; Scherrer AU; Braun DL; Kovari H; Rougemont M; Darling K; Battegay M; Hoffmann M; Bernasconi E; Hirzel C; Günthard HF; Kouyos RD; Swiss HIV Cohort Study a.; Swiss HIV Cohort Study.. The Journal of infectious diseases. 2016.

Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis.

Scherrer AU; von Wyl V; Yang WL; Kouyos RD; Böni J; Yerly S; Klimkait T; Aubert V; Cavassini M; Battegay M; Furrer H; Calmy A; Vernazza P; Bernasconi E; Günthard HF; Swiss HIV Cohort Study.; Aubert V; Battegay M; Bernasconi E; Böni J; Braun DL; Bucher HC; Burton-Jeangros C; Calmy A; Cavassini M; Dollenmaier G; Egger M; Elzi L; Fehr J; Fellay J; Furrer H; Fux CA; Gorgievski M; Günthard H; Haerry D; Hasse B; Hirsch HH; Hoffmann M; Hösli I; Kahlert C; Kaiser L; Keiser O; Klimkait T; Kouyos R; Kovari H; Ledergerber B; Martinetti G; Martinez de Tejada B; Marzolini C; Metzner K; Müller N; Nadal D; Nicca D; Pantaleo G; Rauch A; Regenass S; Rudin C; Schöni-Affolter F; Schmid P; Speck R; Stöckle M; Tarr P; Trkola A; Vernazza P; Weber R; Yerly S. Clinical Infectious Diseases. 2016.

Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons.

Ryom L; Boesecke C; Gisler V; Manzardo C; Rockstroh JK; Puoti M; Furrer H; Miro JM; Gatell JM; Pozniak A; Behrens G; Battegay M; Lundgren JD; EACS Governing Board.. HIV medicine. 2016.

European AIDS Clinical Society Standard of Care meeting on HIV and related coinfections: The Rome Statements.

Mussini C; Antinori A; Bhagani S; Branco T; Brostrom M; Dedes N; Bereczky T; Girardi E; Gökengin D; Horban A; Lacombe K; Lundgren JD; Mendao L; Mocroft A; Oprea C; Porter K; Podlekareva D; Battegay M; d'Arminio Monforte A; European Aids Clinical Society.. HIV medicine. 2016.

Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions.

Salazar-Vizcaya L; Kouyos RD; Zahnd C; Wandeler G; Battegay M; Darling KE; Bernasconi E; Calmy A; Vernazza P; Furrer H; Egger M; Keiser O; Rauch A; Swiss HIV Cohort Study.. Hepatology (Baltimore, Md.). 2016.

HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study.

Marzel A; Shilaih M; Yang WL; Böni J; Yerly S; Klimkait T; Aubert V; Braun DL; Calmy A; Furrer H; Cavassini M; Battegay M; Vernazza PL; Bernasconi E; Günthard HF; Kouyos RD; Swiss HIV Cohort Study.; Aubert V; Battegay M; Bernasconi E; Böni J; Bucher HC; Burton-Jeangros C; Calmy A; Cavassini M; Dollenmaier G; Egger M; Elzi L; Fehr J; Fellay J; Furrer H; Fux CA; Gorgievski M; Günthard HF; Haerry D; Hasse B; Hirsch HH; Hoffmann M; Hösli I; Kahlert C; Kaiser L; Keiser O; Klimkait T; Kouyos RD; Kovari H; Ledergerber B; Martinetti G; de Tejada BM; Metzner K; Müller N; Nadal D; Nicca D; Pantaleo G; Rauch A; Regenass S; Rickenbach M; Rudin C; Schöni-Affolter F; Schmid P; Schüpbach J; Speck R; Tarr P; Trkola A; Vernazza PL; Weber R; Yerly S. Clinical Infectious Diseases. 2016.

Immune recovery in HIV-infected patients after Candida esophagitis is impaired despite long-term antiretroviral therapy.

Stuehler C; Bernardini C; Elzi L; Stoeckle M; Zimmerli S; Furrer H; Günthard HF; Leibundgut-Landmann S; Battegay M; Khanna N; Swiss HIV Cohort Study.. AIDS (London, England). 2016.

Impfungen bei erwachsenen Flüchtlingen

Tarr,P; Notter,J; Sydow,V; Wirz,S; Wallnöfer,A; Vollgraff,M; Neumayr,A; Berger,C; Battegay,M; Fehr,J; Jackson,YL; Posfay-Barbe,K; Durieux,S; Ritz,N; Staehelin,C; Boillat-Blanco,N; Fuchs,S; Martin,B. . 2016.

Implementation and Operational Research: An Integrated and Comprehensive Service Delivery Model to Improve Pediatric and Maternal HIV Care in Rural Africa.

Gamell A; Glass TR; Luwanda LB; Mapesi H; Samson L; Mtoi T; Nyamtema A; Muri L; Ntamatungiro A; Tanner M; Hatz C; Battegay M; Letang E; KIULARCO Study Group.. Journal of Acquired Immune Deficiency Syndromes. 2016.

Infektionen bei erwachsenen Flüchtlingen

Notter,J; Labhardt,N; Hatz,C; Wallnöfer,A; Vollgraff,M; Ritz,N; Wirz,S; Berger,C; Battegay,M; Neumayr,A; Fehr,J; Jackson,YL; Posfay-Barbe,K; Durieux,S; Lanz,C; Staehelin,C; Boillat-Blanco,N; Fuchs,S; Martin,B; Tarr,P. . 2016.

Katzenkratzkrankheit (KKK) – Eine unerwartete Abszessursache nach Mofa-Unfall auf Bali

Zwisler,D; Bloch-Infanger,C; Obermann,EC; Garcia Alzamora,M; Goldenberger,D; Battegay,M. . 2016.

Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared.

Wandeler G; Mulenga L; Vinikoor MJ; Kovari H; Battegay M; Calmy A; Cavassini M; Bernasconi E; Schmid P; Bolton-Moore C; Sinkala E; Chi BH; Egger M; Rauch A; for IeDEA-Southern Africa and the Swiss HIV Cohort Study.. Int J Infect Dis. 2016.

Longer-Term Therapy for Symptoms Attributed to Lyme Disease.

Erb S; Bartels H; Battegay M. The New England journal of medicine. 2016.

Low-Dose Acetylsalicylic Acid Treatment and Impact on Short-Term Mortality in Staphylococcus aureus Bloodstream Infection: A Propensity Score-Matched Cohort Study.

Osthoff M; Sidler JA; Lakatos B; Frei R; Dangel M; Weisser M; Battegay M; Widmer AF. Critical care medicine. 2016.

Prevalence and outcomes of hepatitis B coinfection and associated liver disease among antiretroviral therapy- naive individuals in a rural tanzanian human immunodeficiency virus cohort

Ramirez-Mena A.; Glass T.R.; Winter A.; Kimera N.; Ntamatungiro A.; Hatz C.; Tanner M.; Battegay M.; Furrer H.; Wandeler G.; Letang E.; Asantiel A.; Chale A.; Faini D.; Felger I.; Francis G.; Gamell A.; Glass T.; Hwaya S.; Kalinjuma A.V.; Kasuga B.; Kisunga Y.; Klimkait T.; Luhombero A.; Luwanda L.B.; Mapesi H.; Mbwile L.; Mkulila M.; Mkumbo J.; Mkusa M.; Mnzava D.K.; Mossad G.; Mpundunga D.; Mtandanguo A.; Mwamelo K.; Myeya S.; Nahota S.; Ndaki R.; Ngulukila A.; Ntamatungiro A.J.; Samson L.; Sikalengo G.; Vanobberghen F.; Weisser M.. Open Forum Infectious Diseases. 2016.

Standard Genotyping Overestimates Transmission of Mycobacterium tuberculosis among Immigrants in a Low-Incidence Country

Stucki, David; Ballif, Marie; Egger, Matthias; Furrer, Hansjakob; Altpeter, Ekkehardt; Battegay, Manuel; Droz, Sara; Bruderer, Thomas; Coscolla, Mireia; Borrell, Sonia; Zurcher, Kathrin; Janssens, Jean-Paul; Calmy, Alexandra; Stalder, Jesica Mazza; Jaton, Katia; Rieder, Hans L.; Pfyffer, Gaby E.; Siegrist, Hans H.; Hoffmann, Matthias; Fehr, Jan; Dolina, Marisa; Frei, Reno; Schrenzel, Jacques; Bottger, Erik C.; Gagneux, Sebastien; Fenner, Lukas. JOURNAL OF CLINICAL MICROBIOLOGY. 2016.

Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study.

Scherrer AU; Yang WL; Kouyos RD; Böni J; Yerly S; Klimkait T; Aubert V; Cavassini M; Battegay M; Hauser C; Calmy A; Schmid P; Bernasconi E; Günthard HF; Swiss HIV Cohort Study.. The Journal of infectious diseases. 2016.

Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study.

Scherrer AU; Yang WL; Kouyos RD; Böni J; Yerly S; Klimkait T; Aubert V; Cavassini M; Battegay M; Hauser C; Calmy A; Schmid P; Bernasconi E; Günthard HF; Swiss HIV Cohort Study.. The Journal of infectious diseases. 2016.

The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular Events.

Wandeler G; Kraus D; Fehr J; Conen A; Calmy A; Orasch C; Battegay M; Schmid P; Bernasconi E; Furrer H; Swiss HIV Cohort Study.. Journal of Acquired Immune Deficiency Syndromes. 2016.

Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study.

Gjærde LI; Shepherd L; Jablonowska E; Lazzarin A; Rougemont M; Darling K; Battegay M; Braun D; Martel-Laferriere V; Lundgren JD; Rockstroh JK; Gill J; Rauch A; Mocroft A; Klein MB; Peters L. Clinical Infectious Diseases. 2016.

[Weight loss and chronic diarrhea in a 54-year-old man with HIV infection].

Pickel S; Filipowicz M; Bruder E; Battegay M; Osthoff M. Der Internist. 2015.

A Bundle of Services Increased Ascertainment of Tuberculosis among HIV-Infected Individuals Enrolled in a HIV Cohort in Rural Sub-Saharan Africa.

Haraka,Frederick; Glass,Tracy R; Sikalengo,George; Gamell,Anna; Ntamatungiro,Alex; Hatz,Christoph; Tanner,Marcel; Furrer,Hansjakob; Battegay,Manuel; Letang,Emilio. PLoS One. 2015.

A diagnostic HIV-1 tropism system based on sequence relatedness.

Edwards S; Stucki H; Bader J; Vidal V; Kaiser R; Battegay M; Klimkait T; Swiss HIV Cohort Study.. JOURNAL OF CLINICAL MICROBIOLOGY. 2015.

Assessing efficacy of different nucleos(t)ide backbones in NNRTI-containing regimens in the Swiss HIV Cohort Study

Yang, Wan-Lin; Kouyos, Roger D.; Scherrer, Alexandra U.; Boeni, Juerg; Shah, Cyril; Yerly, Sabine; Klimkait, Thomas; Aubert, Vincent; Hirzel, Cedric; Battegay, Manuel; Cavassini, Matthias; Bernasconi, Enos; Vernazza, Pietro; Held, Leonhard; Ledergerber, Bruno; Guenthard, Huldrych F.. Journal of Antimicrobial Chemotherapy. 2015.

Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012.

Yang WL; Kouyos R; Scherrer AU; Böni J; Shah C; Yerly S; Klimkait T; Aubert V; Furrer H; Battegay M; Cavassini M; Bernasconi E; Vernazza P; Held L; Ledergerber B; Günthard HF; Swiss HIV Cohort Study.. The Journal of infectious diseases. 2015.

Burden of serious fungal infections in Tanzania.

Faini D; Maokola W; Furrer H; Hatz C; Battegay M; Tanner M; Denning DW; Letang E. MYCOSES. 2015.

Combination therapy for multidrug-resistant cytomegalovirus disease.

Stuehler C; Stüssi G; Halter J; Nowakowska J; Schibli A; Battegay M; Dirks J; Passweg J; Heim D; Rovo A; Kalberer C; Bucher C; Weisser M; Dumoulin A; Hirsch HH; Khanna N. Transplant infectious disease : an official journal of the Transplantation Society. 2015.

Correction: A Bundle of Services Increased Ascertainment of Tuberculosis among HIV-Infected Individuals Enrolled in a HIV Cohort in Rural Sub-Saharan Africa.

Haraka F; Glass TR; Sikalengo G; Gamell A; Ntamatungiro A; Hatz C; Tanner M; Furrer H; Battegay M; Letang E. PLoS One. 2015.

Disseminated tuberculosis in an HIV-infected child: rifampicin resistance detected by GeneXpert in a lymph node aspirate but not in cerebrospinal fluid.

Gamell A; Ntamatungiro AJ; Battegay M; Letang E. BMJ case reports. 2015.

Ebola vaccination.

Tschudin-Sutter S; Widmer AF; Emmerich P; Schmidt-Chanasit J; Battegay M. . 2015.

Etravirine: a good option for concomitant use with chemotherapy for Hodgkin's lymphoma.

Kurz M; Stoeckle M; Krasniqi F; Battegay M; Marzolini C. INTERNATIONAL JOURNAL OF STD & AIDS. 2015.

Gender inequalities in the response to combination antiretroviral therapy over time: the Swiss HIV Cohort Study.

Rosin C; Elzi L; Thurnheer C; Fehr J; Cavassini M; Calmy A; Schmid P; Bernasconi E; Battegay M; Swiss HIV Cohort Study.. HIV medicine. 2015.

HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.

Bihl F; Martinetti G; Wandeler G; Weber R; Ledergeber B; Calmy A; Battegay M; Cavassini M; Vernazza P; Caminada AP; Rickenbach M; Bernasconi E; Swiss HIV Cohort Study.. BMC GASTROENTEROLOGY. 2015.

HIV resistance testing and detected drug resistance in Europe

Schultze, Anna; Phillips, Andrew N.; Paredes, Roger; Battegay, Manuel; Rockstroh, Juergen K.; Machala, Ladislav; Tomazic, Janez; Girard, Pierre M.; Januskevica, Inga; Gronborg-Laut, Kamilla; Lundgren, Jens D.; Cozzi-Lepri, Alessandro. AIDS (London, England). 2015.

Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation and Association With Occurrence and Outcome of Invasive Aspergillosis.

Stuehler C; Kuenzli E; Jaeger VK; Baettig V; Ferracin F; Rajacic Z; Kaiser D; Bernardini C; Forrer P; Weisser M; Elzi L; Battegay M; Halter J; Passweg J; Khanna N. The Journal of infectious diseases. 2015.

Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults.

Marzolini C; Sabin C; Raffi F; Siccardi M; Mussini C; Launay O; Burger D; Roca B; Fehr J; Bonora S; Mocroft A; Obel N; Dauchy FA; Zangerle R; Gogos C; Gianotti N; Ammassari A; Torti C; Ghosn J; Chêne G; Grarup J; Battegay M; Efavirenz, Obesity Project Team on behalf of Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.. AIDS (London, England). 2015.

Influence of noninjecting and injecting drug use on mortality, retention in the cohort, and antiretroviral therapy, in participants in the Swiss HIV Cohort Study.

Weber R; Huber M; Battegay M; Stähelin C; Castro Batanjer E; Calmy A; Bregenzer A; Bernasconi E; Schoeni-Affolter F; Ledergerber B; Swiss HIV Cohort Study.. HIV medicine. 2015.

Influenza vaccine response profiles are affected by vaccine preparation and preexisting immunity, but not HIV infection.

Berger CT; Greiff V; Mehling M; Fritz S; Meier MA; Hoenger G; Conen A; Recher M; Battegay M; Reddy ST; Hess C. Human Vaccines & Immunotherapeutics. 2015.

Limitations in study on benefits of clindamycin.

Banderet-Uglioni F; Battegay M; Weisser M; Frei R; Widmer AF. Clinical Infectious Diseases. 2015.

Predicting smoking cessation and its relapse in HIV-infected patients: the Swiss HIV Cohort Study.

Schäfer J; Young J; Bernasconi E; Ledergerber B; Nicca D; Calmy A; Cavassini M; Furrer H; Battegay M; Bucher H; Swiss HIV Cohort Study.. HIV medicine. 2015.

Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality.

Glass TR; Sterne JA; Schneider MP; De Geest S; Nicca D; Furrer H; Günthard HF; Bernasconi E; Calmy A; Rickenbach M; Battegay M; Bucher HC; Swiss HIV Cohort Study.. AIDS (London, England). 2015.

The HIV care cascade in Switzerland: reaching the UNAIDS/WHO targets for patients diagnosed with HIV.

Kohler P; Schmidt AJ; Cavassini M; Furrer H; Calmy A; Battegay M; Bernasconi E; Ledergerber B; Vernazza P; Swiss HIV Cohort Study.. AIDS (London, England). 2015.

The Interplay Between Host Genetic Variation, Viral Replication, and Microbial Translocation in Untreated HIV-Infected Individuals.

Perkins MR; Bartha I; Timmer JK; Liebner JC; Wolinsky D; Günthard HF; Hauser C; Bernasconi E; Hoffmann M; Calmy A; Battegay M; Telenti A; Douek DC; Fellay J; Swiss HIV Cohort Study.. The Journal of infectious diseases. 2015.

Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study.

Young J; Rickenbach M; Calmy A; Bernasconi E; Staehelin C; Schmid P; Cavassini M; Battegay M; Günthard HF; Bucher HC; Swiss HIV Cohort Study.. BMC Infectious Diseases. 2015.

[Antiretroviral therapy].

von Braun,Amrei; Furrer,Hansjakob; Battegay,Manuel; Calmy,Alexandra; Cavassini,Matthias; Vernazza,Pietro; Bernasconi,Enos; Weber,Rainer; Günthard,Huldrych F. Therapeutische Umschau. 2014.

[Epidemiology of HIV].

Ledergerber B; Battegay M. Therapeutische Umschau. 2014.

[Psychosocial aspects on the treatment of HIV-infection].

Battegay M; Haerry DH; Fehr J; Staehelin C; Wandeler G; Elzi L. Therapeutische Umschau. 2014.

Antiretroviral therapy after cryptococcal meningitis.

Hirsch HH; Wehrle-Wieland E; Battegay M. The New England journal of medicine. 2014.

A short tool to screen HIV-infected patients for mild neurocognitive disorders - a pilot study.

Fasel D; Kunze U; Elzi L; Werder V; Niepmann S; Monsch AU; Schumacher R; Battegay M. BMC Psychol. 2014.

cART prescription trends in a prospective HIV cohort in rural Tanzania from 2007 to 2011.

Franzeck FC; Letang E; Mwaigomole G; Jullu B; Glass TR; Nyogea D; Hatz C; Tanner M; Battegay M. BMC Infectious Diseases. 2014.

Choice of initial therapy.

Battegay M. Journal of the International AIDS Society. 2014.

Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study.

Hasse B; Walker AS; Fehr J; Furrer H; Hoffmann M; Battegay M; Calmy A; Fellay J; Di Benedetto C; Weber R; Ledergerber B; Swiss HIV Cohort Study.. Antimicrobial agents and chemotherapy. 2014.

Disentangling human tolerance and resistance against HIV.

Regoes RR; McLaren PJ; Battegay M; Bernasconi E; Calmy A; Günthard HF; Hoffmann M; Rauch A; Telenti A; Fellay J; Swiss HIV Cohort Study.. PLOS BIOLOGY. 2014.

Does HIV antiretroviral therapy still need its backbone?

Battegay M; Elzi L. Lancet (London, England). 2014.

Enterococci, Clostridium difficile and ESBL-producing bacteria: epidemiology, clinical impact and prevention in ICU patients.

Sidler JA; Battegay M; Tschudin-Sutter S; Widmer AF; Weisser M. Schweizerische Medizinische Wochenschrift. 2014.

Evaluation of treatment outcomes for Stenotrophomonas maltophilia bacteraemia.

Lakatos B; Jakopp B; Widmer A; Frei R; Pargger H; Elzi L; Battegay M. Infection. 2014.

High colonization rates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in Swiss travellers to South Asia- a prospective observational multicentre cohort study looking at epidemiology, microbiology and risk factors.

Kuenzli E; Jaeger VK; Frei R; Neumayr A; DeCrom S; Haller S; Blum J; Widmer AF; Furrer H; Battegay M; Endimiani A; Hatz C. BMC Infectious Diseases. 2014.

IL-28B is a key regulator of B- and T-cell vaccine responses against influenza.

Egli A; Santer DM; O'Shea D; Barakat K; Syedbasha M; Vollmer M; Baluch A; Bhat R; Groenendyk J; Joyce MA; Lisboa LF; Thomas BS; Battegay M; Khanna N; Mueller T; Tyrrell DL; Houghton M; Humar A; Kumar D. PLoS pathogens. 2014.

Is switching to an oral antibiotic regimen safe after 2 weeks of intravenous treatment for primary bacterial vertebral osteomyelitis?

Babouee Flury B; Elzi L; Kolbe M; Frei R; Weisser M; Schären S; Widmer AF; Battegay M. BMC Infectious Diseases. 2014.

Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study.

Hasse B; Iff M; Ledergerber B; Calmy A; Schmid P; Hauser C; Cavassini M; Bernasconi E; Marzolini C; Tarr PE; Swiss HIV Cohort Study.; Aubert V; Barth J; Battegay M; Bernasconi E; Böni J; Bucher HC; Burton-Jeangros C; Calmy A; Cavassini M; Egger M; Elzi L; Fehr J; Fellay J; Furrer H; Fux CA; Gorgievski M; Günthard H; Haerry D; Hasse B; Hirsch HH; Hösli I; Kahlert C; Kaiser L; Keiser O; Klimkait T; Kouyos R; Kovari H; Ledergerber B; Martinetti G; Martinez de Tejada B; Metzner K; Müller N; Nadal D; Pantaleo G; Rauch A; Regenass S; Rickenbach M; Rudin C; Schöni-Affolter F; Schmid P; Schultze D; Schüpbach J; Speck R; Staehelin C; Tarr P; Telenti A; Trkola A; Vernazza P; Weber R; Yerly S. Open Forum Infectious Diseases. 2014.

Performances of two different panfungal PCRs to detect mould DNA in formalin-fixed paraffin-embedded tissue: what are the limiting factors?

Babouee Flury B; Weisser M; Prince SS; Bubendorf L; Battegay M; Frei R; Goldenberger D. BMC Infectious Diseases. 2014.

Surgical and antimicrobial treatment of prosthetic vascular graft infections at different surgical sites: a retrospective study of treatment outcomes.

Erb S; Sidler JA; Elzi L; Gurke L; Battegay M; Widmer AF; Weisser M. PLoS One. 2014.

The rate of recovery in renal function when patients with HIV infection discontinue treatment with tenofovir.

Young J; Wang Q; Fux CA; Bernasconi E; Furrer H; Vernazza P; Calmy A; Cavassini M; Weber R; Battegay M; Bucher HC; Swiss HIV Cohort Study.. HIV medicine. 2014.

Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease.

Borges ÁH; Lundgren JD; Ridolfo A; Katlama C; Antunes F; Grzeszczuk A; Blaxhult A; Mitsura VM; Doroana M; Battegay M; Gargalianos P; Mocroft A; EuroSIDA in EuroCOORD.. AIDS (London, England). 2014.

Treatment-naive individuals are the major source of transmitted HIV-1 drug resistance in men who have sex with men in the Swiss HIV Cohort Study.

Drescher SM; von Wyl V; Yang WL; Böni J; Yerly S; Shah C; Aubert V; Klimkait T; Taffé P; Furrer H; Battegay M; Ambrosioni J; Cavassini M; Bernasconi E; Vernazza PL; Ledergerber B; Günthard HF; Kouyos RD; Swiss HIV Cohort Study.. Clinical Infectious Diseases. 2014.

Vaccine adjuvants--understanding molecular mechanisms to improve vaccines.

Egli A; Santer D; Barakat K; Zand M; Levin A; Vollmer M; Weisser M; Khanna N; Kumar D; Tyrrell L; Houghton M; Battegay M; O'Shea D. Schweizerische Medizinische Wochenschrift. 2014.

Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone.

Wang Q; Young J; Bernasconi E; Vernazza P; Calmy A; Cavassini M; Furrer H; Fehr J; Bucher HC; Battegay M; Swiss HIV Cohort Study.. HIV clinical trials. 2014.

[Clinical infectious diseases : interdisciplinary and unique].

Battegay M; Fätkenheuer G; Kern WV. Der Internist. 2013.

[Initial patient assessment of infectious diseases and diagnostic steps with fever].

Schibli A; Weisser M; Bingisser R; Widmer AF; Battegay M. Der Internist. 2013.

[Prevention of catheter-related infections: minimizing secondary complications in geriatric patients].

Schwaiger K; Christ M; Battegay M; Heppner HJ. ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE. 2013.

Association of alcohol consumption and HIV surrogate markers in participants of the swiss HIV cohort study.

Conen A; Wang Q; Glass TR; Fux CA; Thurnheer MC; Orasch C; Calmy A; Bernasconi E; Vernazza P; Weber R; Bucher HC; Battegay M; Fehr J. Journal of Acquired Immune Deficiency Syndromes. 2013.

Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study.

Weber R; Ruppik M; Rickenbach M; Spoerri A; Furrer H; Battegay M; Cavassini M; Calmy A; Bernasconi E; Schmid P; Flepp M; Kowalska J; Ledergerber B; Swiss HIV Cohort Study (SHCS).. HIV medicine. 2013.

Expansion of interferon-γ-secreting HIV-specific T cells during successful antiretroviral therapy.

Gasser O; Brander C; Wolbers M; Brown NV; Rauch A; Günthard HF; Battegay M; Hess C; Swiss HIV Cohort Study.. HIV medicine. 2013.

Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study.

Wandeler G; Gsponer T; Bihl F; Bernasconi E; Cavassini M; Kovari H; Schmid P; Battegay M; Calmy A; Egger M; Furrer H; Rauch A; Swiss HIV Cohort Study.. The Journal of infectious diseases. 2013.

HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosis.

Fenner L; Egger M; Bodmer T; Furrer H; Ballif M; Battegay M; Helbling P; Fehr J; Gsponer T; Rieder HL; Zwahlen M; Hoffmann M; Bernasconi E; Cavassini M; Calmy A; Dolina M; Frei R; Janssens JP; Borrell S; Stucki D; Schrenzel J; Böttger EC; Gagneux S; Swiss HIV Cohort and Molecular Epidemiology of Tuberculosis Study Groups.. PLoS Genetics. 2013.

Improved services to enrollees into an HIV rural care and treatment center in Tanzania.

Said K; Mkopi A; Verver S; Lwilla F; Churchyard G; Shekalaghe S; Battegay M; Reither K. The Pan African medical journal. 2013.

Low levels of mannan-binding lectin or ficolins are not associated with an increased risk of cytomegalovirus disease in HIV-infected patients.

Egli A; Schäfer J; Osthoff M; Thiel S; Mikkelsen C; Rauch A; Hirsch HH; Bucher HC; Young J; Jensenius JC; Battegay M; Trendelenburg M; Swiss HIV Cohort Study.. PLoS One. 2013.

Prospective study of a panfungal PCR assay followed by sequencing, for the detection of fungal DNA in normally sterile specimens in a clinical setting: a complementary tool in the diagnosis of invasive fungal disease?

Babouee B; Goldenberger D; Elzi L; Lardinois D; Sadowski-Cron C; Bubendorf L; Savic Prince S; Battegay M; Frei R; Weisser M. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2013.

Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS).

Nüesch R; Wang Q; Elzi L; Bernasconi E; Weber R; Cavassini M; Vernazza P; Thurnheer MC; Calmy A; Battegay M; Bucher HC; Swiss HIV Cohort Study.. Journal of Acquired Immune Deficiency Syndromes. 2013.

Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA.

Grint D; Peters L; Schwarze-Zander C; Beniowski M; Pradier C; Battegay M; Jevtovic D; Soriano V; Lundgren JD; Rockstroh JK; Kirk O; Mocroft A; EuroSIDA in EuroCoord.. HIV medicine. 2013.

The Individualized Genetic Barrier Predicts Treatment Response in a Large Cohort of HIV-1 Infected Patients

Beerenwinkel, Niko; Montazeri, Hesam; Schuhmacher, Heike; Knupfer, Patrick; von Wyl, Viktor; Furrer, Hansjakob; Battegay, Manuel; Hirschel, Bernard; Cavassini, Matthias; Vernazza, Pietro; Bernasconi, Enos; Yerly, Sabine; Boeni, Juerg; Klimkait, Thomas; Cellerai, Cristina; Guenthard, Huldrych F.. PLoS Computational Biology. 2013.

Uptake of guidelines on prevention of mother-to-child transmission of HIV in rural Tanzania: time for change

Gamell, Anna; Letang, Emili; Jullu, Boniface; Mwaigomole, Geoffrey; Nyamtema, Angelo; Hatz, Christoph; Battegay, Manuel; Tanner, Marcel. Swiss medical weekly. 2013.

Viral hepatitis and rapid diagnostic test based screening for HBsAg in HIV-infected patients in rural Tanzania.

Franzeck FC; Ngwale R; Msongole B; Hamisi M; Abdul O; Henning L; Letang E; Mwaigomole G; Battegay M; Hatz C; Tanner M. PLoS One. 2013.

[Fever, coughing and dyspnea in a 38-year-old female kidney transplant recipient].

Porsche M; Künzli E; Dickenmann M; Hirsch HH; Battegay M; Khanna N. Der Internist. 2012.

[Morbidity and mortality in HIV infection].

Stöckle M; Elzi L; Rockstroh JK; Battegay M. Der Internist. 2012.

[Prevention of catheter-related infections].

Schwaiger K; Christ M; Battegay M; Widmer A. Der Internist. 2012.

Beneficial course of two cases of HIV-associated multicentric Castleman disease treated with HIV antiretroviral therapy.

Rosin C; Hostettler F; Elzi L; Dirnhofer S; Battegay M. AIDS (London, England). 2012.

Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection Determinants and Outcomes

Elzi, Luigia; Erb, Stefan; Furrer, Hansjakob; Ledergerber, Bruno; Cavassini, Matthias; Hirschel, Bernard; Vernazza, Pietro; Bernasconi, Enos; Weber, Rainer; Battegay, Manuel. ARCHIVES OF INTERNAL MEDICINE. 2012.

Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy.

Glass TR; Rotger M; Telenti A; Decosterd L; Csajka C; Bucher HC; Günthard HF; Rickenbach M; Nicca D; Hirschel B; Bernasconi E; Wandeler G; Battegay M; Marzolini C; Swiss HIV Cohort Study.. PLoS One. 2012.

Do we need national guidelines on human immunodeficiency virus treatment?

Letang E; Battegay M. ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA. 2012.

Efavirenz in an obese HIV-infected patient - a report and an in vitro-in vivo extrapolation model indicate risk of underdosing

de Roche, Mirjam; Siccardi, Marco; Stoeckle, Marcel; Livio, Francoise; Back, David; Battegay, Manuel; Marzolini, Catia. Antiviral therapy. 2012.

Genetic diversity of EBV-encoded LMP1 in the Swiss HIV Cohort Study and implication for NF-Κb activation.

Zuercher E; Butticaz C; Wyniger J; Martinez R; Battegay M; Boffi El Amari E; Dang T; Egger JF; Fehr J; Mueller-Garamvögyi E; Parini A; Schaefer SC; Schoeni-Affolter F; Thurnheer C; Tinguely M; Telenti A; Rothenberger S; Swiss HIV Cohort Study.. PLoS One. 2012.

HLA-Bw4 identifies a population of HIV-infected patients with an increased capacity to control viral replication after structured treatment interruption.

Stern M; Czaja K; Rauch A; Rickenbach M; Günthard HF; Battegay M; Fellay J; Hirschel B; Hess C; Swiss HIV Cohort Study Group.. HIV medicine. 2012.

How to discriminate contamination from bloodstream infection due to coagulase-negative staphylococci: a prospective study with 654 patients.

Elzi L; Babouee B; Vögeli N; Laffer R; Dangel M; Frei R; Battegay M; Widmer AF. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2012.

Human metapneumovirus infection after allogeneic hematopoietic stem cell transplantation.

Egli A; Bucher C; Dumoulin A; Stern M; Buser A; Bubendorf L; Gregor M; Servida P; Sommer G; Bremerich J; Gratwohl A; Khanna N; Widmer AF; Battegay M; Tamm M; Hirsch HH; Halter JP. Infection. 2012.

Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations.

von Wyl V; Yerly S; Böni J; Shah C; Cellerai C; Klimkait T; Battegay M; Bernasconi E; Cavassini M; Furrer H; Hirschel B; Vernazza PL; Ledergerber B; Günthard HF; Swiss HIV Cohort Study.. Clinical Infectious Diseases. 2012.

Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection.

Clifford GM; Lise M; Franceschi S; Egger M; Bouchardy C; Korol D; Levi F; Ess S; Jundt G; Wandeler G; Fehr J; Schmid P; Battegay M; Bernasconi E; Cavassini M; Calmy A; Keiser O; Schöni-Affolter F; Swiss HIV Cohort Study.. BRITISH JOURNAL OF CANCER. 2012.

Mycobacterium tuberculosis Transmission in a Country with Low Tuberculosis Incidence: Role of Immigration and HIV Infection

Fenner, Lukas; Gagneux, Sebastien; Helbling, Peter; Battegay, Manuel; Rieder, Hans L.; Pfyffer, Gaby E.; Zwahlen, Marcel; Furrer, Hansjakob; Siegrist, Hans H.; Fehr, Jan; Dolina, Marisa; Calmy, Alexandra; Stucki, David; Jaton, Katia; Janssens, Jean-Paul; Stalder, Jesica Mazza; Bodmer, Thomas; Ninet, Beatrice; Boettger, Erik C.; Egger, Matthias. JOURNAL OF CLINICAL MICROBIOLOGY. 2012.

New approaches to the management of hepatitis C in haemophilia in 2012.

Battegay,M; Rockstroh,J K. HAEMOPHILIA. 2012.

No risk of surgical site infections from residual bacteria after disinfection with povidone-iodine-alcohol in 1014 cases: a prospective observational study.

Tschudin-Sutter S; Frei R; Egli-Gany D; Eckstein F; Valderrabano V; Dangel M; Battegay M; Widmer AF. Annals of surgery. 2012.

Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians.

Huber M; Ledergerber B; Sauter R; Young J; Fehr J; Cusini A; Battegay M; Calmy A; Orasch C; Nicca D; Bernasconi E; Jaccard R; Held L; Weber R; Swiss HIV Cohort Study Group.. HIV medicine. 2012.

Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.

Young,Jim; Schäfer,Juliane; Fux,Christoph A; Furrer,Hansjakob; Bernasconi,Enos; Vernazza,Pietro; Calmy,Alexandra; Cavassini,Matthias; Weber,Rainer; Battegay,Manuel; Bucher,Heiner C; Swiss HIV Cohort Study. AIDS (London, England). 2012.

Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo.

Pillai SK; Abdel-Mohsen M; Guatelli J; Skasko M; Monto A; Fujimoto K; Yukl S; Greene WC; Kovari H; Rauch A; Fellay J; Battegay M; Hirschel B; Witteck A; Bernasconi E; Ledergerber B; Günthard HF; Wong JK; Swiss HIV Cohort Study.. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2012.

Skin problems in immunodeficient patients.

Itin PH; Battegay M. Current problems in dermatology. 2012.

Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study.

Bucher HC; Richter W; Glass TR; Magenta L; Wang Q; Cavassini M; Vernazza P; Hirschel B; Weber R; Furrer H; Battegay M; Bernasconi E. Journal of Acquired Immune Deficiency Syndromes. 2012.

[Drug-drug interactions with HIV treatments].

Mossdorf E; Marzolini C; Fasel D; Mello Fayet A; Blum C; Donath M; Battegay M. Praxis. 2011.

[Of bugs and joints. Oligoarthritis caused by Tropheryma whipplei].

Koligi K; Mertz D; Benz D; Vogt T; Bloemberg GV; Winter L; Tyndall A; Battegay M; Walker UA. Der Internist. 2011.

[Vaccination: advances and evidence].

Battegay M; Manns MP. Der Internist. 2011.

[Vaccination against pneumococci and influenza. How good is the evidence?].

Babouee B; Widmer AF; Battegay M. Der Internist. 2011.

Ageing with HIV: medication use and risk for potential drug-drug interactions.

Marzolini C; Back D; Weber R; Furrer H; Cavassini M; Calmy A; Vernazza P; Bernasconi E; Khoo S; Battegay M; Elzi L; Swiss HIV Cohort Study Members.. Journal of Antimicrobial Chemotherapy. 2011.

Ambiguous nucleotide calls from population-based sequencing of HIV-1 are a marker for viral diversity and the age of infection.

Kouyos RD; von Wyl V; Yerly S; Böni J; Rieder P; Joos B; Taffé P; Shah C; Bürgisser P; Klimkait T; Weber R; Hirschel B; Cavassini M; Rauch A; Battegay M; Vernazza PL; Bernasconi E; Ledergerber B; Bonhoeffer S; Günthard HF; Swiss HIV Cohort Study.. Clinical Infectious Diseases. 2011.

Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples.

Anglemyer A; Rutherford GW; Egger M; Siegfried N. Cochrane Database of Systematic Reviews. 2011.

Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.

Battegay M; Arasteh K; Plettenberg A; Bogner JR; Livrozet JM; Witt MD; Mossdorf E; Yong CL; Zhang W; Macha S; Berger F; Stern J; Robinson P; Quinson AM. CLINICAL THERAPEUTICS. 2011.

Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque.

Rotger M; Dalmau J; Rauch A; McLaren P; Bosinger SE; Martinez R; Sandler NG; Roque A; Liebner J; Battegay M; Bernasconi E; Descombes P; Erkizia I; Fellay J; Hirschel B; Miró JM; Palou E; Hoffmann M; Massanella M; Blanco J; Woods M; Günthard HF; de Bakker P; Douek DC; Silvestri G; Martinez-Picado J; Telenti A. The Journal of clinical investigation. 2011.

Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption

von Wyl, Viktor; Gianella, Sara; Fischer, Marek; Niederoest, Barbara; Kuster, Herbert; Battegay, Manuel; Bernasconi, Enos; Cavassini, Matthias; Rauch, Andri; Hirschel, Bernard; Vernazza, Pietro; Weber, Rainer; Joos, Beda; Guenthard, Huldrych F.. PLoS One. 2011.

Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA.

Gianella S; von Wyl V; Fischer M; Niederoest B; Battegay M; Bernasconi E; Cavassini M; Rauch A; Hirschel B; Vernazza P; Weber R; Joos B; Günthard HF; Swiss HIV Cohort Study.. Antiviral therapy. 2011.

Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study.

Young J; Scherrer AU; Günthard HF; Opravil M; Yerly S; Böni J; Rickenbach M; Fux CA; Cavassini M; Bernasconi E; Vernazza P; Hirschel B; Battegay M; Bucher HC; Swiss HIV Cohort Study.. HIV medicine. 2011.

Emergence of glutaraldehyde-resistant Pseudomonas aeruginosa.

Tschudin-Sutter S; Frei R; Kampf G; Tamm M; Pflimlin E; Battegay M; Widmer AF. Infection control and hospital epidemiology. 2011.

Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance.

di Iulio J; Ciuffi A; Fitzmaurice K; Kelleher D; Rotger M; Fellay J; Martinez R; Pulit S; Furrer H; Günthard HF; Battegay M; Bernasconi E; Schmid P; Hirschel B; Barnes E; Klenerman P; Telenti A; Rauch A; Swiss HIV Cohort Study.. Hepatology (Baltimore, Md.). 2011.

Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition.

Mossdorf E; Stoeckle M; Mwaigomole EG; Chiweka E; Kibatala PL; Geubbels E; Urassa H; Abdulla S; Elzi L; Tanner M; Furrer H; Hatz C; Battegay M. BMC INFECTIOUS DISEASES. 2011.

Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB™) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection.

Elzi L; Steffen I; Furrer H; Fehr J; Cavassini M; Hirschel B; Hoffmann M; Bernasconi E; Bassetti S; Battegay M. BMC Infectious Diseases. 2011.

Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death.

Kaufmann GR; Elzi L; Weber R; Furrer H; Giulieri S; Vernazza P; Bernasconi E; Hirschel B; Battegay M; Swiss HIV Cohort Study.. AIDS (London, England). 2011.

Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study.

Hasse B; Ledergerber B; Furrer H; Battegay M; Hirschel B; Cavassini M; Bertisch B; Bernasconi E; Weber R; Swiss HIV Cohort Study.. Clinical Infectious Diseases. 2011.

Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study.

Fehr J; Glass TR; Louvel S; Hamy F; Hirsch HH; von Wyl V; Böni J; Yerly S; Bürgisser P; Cavassini M; Fux CA; Hirschel B; Vernazza P; Martinetti G; Bernasconi E; Günthard HF; Battegay M; Bucher HC; Klimkait T; Swiss HIV Cohort Study.. Journal of Translational Medicine. 2011.

Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection.

Haas A; Zimmermann K; Graw F; Slack E; Rusert P; Ledergerber B; Bossart W; Weber R; Thurnheer MC; Battegay M; Hirschel B; Vernazza P; Patuto N; Macpherson AJ; Günthard HF; Oxenius A; Swiss HIV Cohort Study.. Gut. 2011.

The Role of Migration and Domestic Transmission in the Spread of HIV-1 Non-B Subtypes in Switzerland

von Wyl, Viktor; Kouyos, Roger D.; Yerly, Sabine; Boeni, Juerg; Shah, Cyril; Buergisser, Philippe; Klimkait, Thomas; Weber, Rainer; Hirschel, Bernard; Cavassini, Matthias; Staehelin, Cornelia; Battegay, Manuel; Vernazza, Pietro L.; Bernasconi, Enos; Ledergerber, Bruno; Bonhoeffer, Sebastian; Guenthard, Huldrych F.. The Journal of infectious diseases. 2011.

Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study.

Ledergerber B; Cavassini M; Battegay M; Bernasconi E; Vernazza P; Hirschel B; Furrer H; Rickenbach M; Weber R; Swiss HIV Cohort Study.. HIV medicine. 2011.

Viral suppression rates in salvage treatment with raltegravir improved with the administration of genotypic partially active or inactive nucleoside/tide reverse transcriptase inhibitors.

Scherrer AU; von Wyl V; Böni J; Yerly S; Klimkait T; Bürgisser P; Garzoni C; Hirschel B; Cavassini M; Battegay M; Vernazza PL; Bernasconi E; Ledergerber B; Günthard HF; Swiss HIV Cohort Study (SHCS).. Journal of Acquired Immune Deficiency Syndromes. 2011.

[42-year-old obese man with H1N1 influenza A infection necessitating mechanical ventilation].

Daneschwar F; Tschudin Sutter S; Widmer AF; Battegay M. Der Internist. 2010.

[Postoperative wound infections: essentials for the internal medicine].

Widmer AF; Battegay M. Der Internist. 2010.

[Prevention of infections].

Widmer A; Gastmeier P; Battegay M. Der Internist. 2010.

Antiretroviral monotherapy: should we abandon the principles of successful antiretroviral therapy?

Battegay M; Bucher HC. AIDS (London, England). 2010.

A rifampicin-containing antibiotic treatment improves outcome of staphylococcal deep sternal wound infections.

Khanlari B; Elzi L; Estermann L; Weisser M; Brett W; Grapow M; Battegay M; Widmer AF; Flückiger U. Journal of Antimicrobial Chemotherapy. 2010.

Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy.

Rohrbach J; Robinson N; Harcourt G; Hammond E; Gaudieri S; Gorgievski M; Telenti A; Keiser O; Günthard HF; Hirschel B; Hoffmann M; Bernasconi E; Battegay M; Furrer H; Klenerman P; Rauch A; Swiss HIV Cohort Study.. Gut. 2010.

Comparison of infectious complications during induction/consolidation chemotherapy versus allogeneic hematopoietic stem cell transplantation.

Orasch C; Weisser M; Mertz D; Conen A; Heim D; Christen S; Gratwohl A; Battegay M; Widmer A; Flückiger U. Bone marrow transplantation. 2010.

Eradication of an epidemic methicillin-resistant Staphylococcus aureus (MRSA) from a geriatric university hospital: evidence from a 10-year follow-up.

Mertz D; Frei R; Periat N; Scheidegger C; Battegay M; Seiler W; Widmer AF. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 2010.

Extended spectrum ß-lactamase-producing Escherichia coli in neonatal care unit.

Tschudin-Sutter S; Frei R; Battegay M; Hoesli I; Widmer AF. EMERGING INFECTIOUS DISEASES. 2010.

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study.

Rauch A; Kutalik Z; Descombes P; Cai T; Di Iulio J; Mueller T; Bochud M; Battegay M; Bernasconi E; Borovicka J; Colombo S; Cerny A; Dufour JF; Furrer H; Günthard HF; Heim M; Hirschel B; Malinverni R; Moradpour D; Müllhaupt B; Witteck A; Beckmann JS; Berg T; Bergmann S; Negro F; Telenti A; Bochud PY; Swiss Hepatitis C Cohort Study.; Swiss HIV Cohort Study.. Gastroenterology. 2010.

Impact of a national HIV voluntary counselling and testing (VCT) campaign on VCT in a rural hospital in Tanzania.

Mossdorf E; Stoeckle M; Vincenz A; Mwaigomole EG; Chiweka E; Kibatala P; Urassa H; Abdulla S; Elzi L; Tanner M; Furrer H; Hatz C; Battegay M. Tropical Medicine and International Health. 2010.

Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection.

Kovari H; Ledergerber B; Battegay M; Rauch A; Hirschel B; Foguena AK; Vernazza P; Bernasconi E; Mueller NJ; Weber R. Clinical Infectious Diseases. 2010.

Infektionskrankheiten

Battegay,M; Flückiger,U; Stellbrink,HJ; Shah,PM. . 2010.

Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study.

Glass TR; Battegay M; Cavassini M; De Geest S; Furrer H; Vernazza PL; Hirschel B; Bernasconi E; Rickenbach M; Günthard HF; Bucher HC; Swiss HIV Cohort Study.. Journal of Acquired Immune Deficiency Syndromes. 2010.

Low postseroconversion CD4 count and rapid decrease of CD4 density identify HIV+ fast progressors.

Audigé A; Taffé P; Rickenbach M; Battegay M; Vernazza P; Nadal D; Speck RF; Swiss HIV Cohort Study (SHCS).. AIDS RESEARCH AND HUMAN RETROVIRUSES. 2010.

Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland.

Kouyos RD; von Wyl V; Yerly S; Böni J; Taffé P; Shah C; Bürgisser P; Klimkait T; Weber R; Hirschel B; Cavassini M; Furrer H; Battegay M; Vernazza PL; Bernasconi E; Rickenbach M; Ledergerber B; Bonhoeffer S; Günthard HF. The Journal of infectious diseases. 2010.

Pregnancy and delivery outcomes of HIV infected women in Switzerland 2003-2008.

Aebi-Popp K; Lapaire O; Glass TR; Vilén L; Rudin C; Elzi L; Battegay M; Keiser O; de Tejada BM; Hoesli IM; Swiss Mother And Child HIV Cohort Study.. JOURNAL OF PERINATAL MEDICINE. 2010.

Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study.

Marzolini C; Elzi L; Gibbons S; Weber R; Fux C; Furrer H; Chave JP; Cavassini M; Bernasconi E; Calmy A; Vernazza P; Khoo S; Ledergerber B; Back D; Battegay M; Swiss HIV Cohort Study.. Antiviral therapy. 2010.

Primary cytomegalovirus infection with accompanying Pneumocystis jiroveci pneumonia in a patient with large-vessel vasculitis.

Vetter M; Battegay M; Trendelenburg M. Infection. 2010.

Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection.

Opravil M; Klimkait T; Louvel S; Wolf E; Battegay M; Fux CA; Bernasconi E; Vogel M; Speck R; Weber R; Swiss HIV Cohort Study.. Journal of Acquired Immune Deficiency Syndromes. 2010.

Randomized trial of a computerized coronary heart disease risk assessment tool in HIV-infected patients receiving combination antiretroviral therapy.

Bucher HC; Rickenbach M; Young J; Glass TR; Vallet Y; Bernasconi E; Cavassini M; Fux C; Schiffer V; Vernazza P; Weber R; Battegay M; Swiss HIV Cohort Study.. Antiviral therapy. 2010.

Stronger correlation between antibiotic use and the incidence of Clostridium difficile determined by culture results instead of faecal toxin detection only.

Mertz D; Frei R; Plagge H; Battegay M; Widmer AF. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 2010.

Suicide in HIV-infected individuals and the general population in Switzerland, 1988-2008.

Keiser O; Spoerri A; Brinkhof MW; Hasse B; Gayet-Ageron A; Tissot F; Christen A; Battegay M; Schmid P; Bernasconi E; Egger M; Swiss HIV Cohort Study.; Swiss National Cohort.. AMERICAN JOURNAL OF PSYCHIATRY. 2010.

Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.

Elzi L; Marzolini C; Furrer H; Ledergerber B; Cavassini M; Hirschel B; Vernazza P; Bernasconi E; Weber R; Battegay M; Swiss HIV Cohort Study.. ARCHIVES OF INTERNAL MEDICINE. 2010.

Virosomal influenza-vaccine induced immunity in HIV-infected individuals with high versus low CD4+ T-cell counts: clues towards a rational vaccination strategy.

Fritz S; Mossdorf E; Durovic B; Zenhaeusern G; Conen A; Steffen I; Battegay M; Nüesch R; Hess C. AIDS (London, England). 2010.

"Rechercheservice Evidenzbasierte Medizin (REM)" - an internet based tool to implement evidence based medicine in primary care

Rinnerberger, A.; Doerfler, C.; Grafinger, M.; Soennichsen, A.. Der Internist. 2009.

[53 year-old patient with fever and cough].

Orasch C; Battegay M. Der Internist. 2009.

[Mucocutaneous infections in immunosuppression].

Itin PH; Battegay M. Der Internist. 2009.

[The skin, an interdisciplinary organ].

Itin PH; Hengge UR; Battegay M. Der Internist. 2009.

CD4(+) T cell count decreases by ethnicity among untreated patients with HIV infection in South Africa and Switzerland.

May M; Wood R; Myer L; Taffé P; Rauch A; Battegay M; Egger M; Cape Town AIDS Cohort.; Swiss HIV Cohort Study.. The Journal of infectious diseases. 2009.

Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study.

Rotger M; Bayard C; Taffé P; Martinez R; Cavassini M; Bernasconi E; Battegay M; Hirschel B; Furrer H; Witteck A; Weber R; Ledergerber B; Telenti A; Tarr PE; Swiss HIV Cohort Study.. Circulation-Cardiovascular Genetics. 2009.

Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals.

Elzi L; Kaufmann G; Weber R; Fux CA; Cavassini M; Hirschel B; Vernazza P; Bernasconi E; Battegay M; Swiss HIV Cohort Study.. HIV clinical trials. 2009.

Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus.

Mertz D; Battegay M; Marzolini C; Mayr M. AMERICAN JOURNAL OF KIDNEY DISEASES. 2009.

Exclusive Staphylococcus aureus throat carriage: at-risk populations.

Mertz D; Frei R; Periat N; Zimmerli M; Battegay M; Flückiger U; Widmer AF. ARCHIVES OF INTERNAL MEDICINE. 2009.

Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy.

Young J; Glass TR; Bernasconi E; Rickenbach M; Furrer H; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC; Swiss HIV Cohort Study.. Journal of clinical epidemiology. 2009.

Hodgkin lymphoma in the Swiss HIV Cohort Study.

Clifford GM; Rickenbach M; Lise M; Dal Maso L; Battegay M; Bohlius J; Boffi El Amari E; Karrer U; Jundt G; Bordoni A; Ess S; Franceschi S; Swiss HIV Cohort Study.. Blood. 2009.

How reliable is an undetectable viral load?

Combescure C; Vallier N; Ledergerber B; Cavassini M; Furrer H; Rauch A; Battegay M; Bernasconi E; Vernazza P; Hirschel B; Swiss HIV Cohort Study.. HIV medicine. 2009.

Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007.

Ballif M; Ledergerber B; Battegay M; Cavassini M; Bernasconi E; Schmid P; Hirschel B; Furrer H; Rickenbach M; Opravil M; Weber R; Swiss HIV Cohort Study.. PLoS One. 2009.

Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study.

Khanna N; Elzi L; Mueller NJ; Garzoni C; Cavassini M; Fux CA; Vernazza P; Bernasconi E; Battegay M; Hirsch HH; Swiss HIV Cohort Study.. Clinical Infectious Diseases. 2009.

Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.

Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group.; Bohlius J; Schmidlin K; Costagliola D; Fätkenheuer G; May M; Caro-Murillo AM; Mocroft A; Bonnet F; Clifford G; Karafoulidou A; Miro JM; Lundgren J; Chene G; Egger M. Antiviral therapy. 2009.

Influence of antiretroviral therapy on programmed death-1 (CD279) expression on T cells in lymph nodes of human immunodeficiency virus-infected individuals.

Ehrhard S; Wernli M; Dürmüller U; Battegay M; Gudat F; Erb P. Human Pathology. 2009.

Interruption of antiretroviral therapy is associated with increased plasma cystatin C.

Mocroft A; Wyatt C; Szczech L; Neuhaus J; El-Sadr W; Tracy R; Kuller L; Shlipak M; Angus B; Klinker H; Ross M; INSIGHT SMART Study Group.. AIDS (London, England). 2009.

JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy.

Khanna N; Wolbers M; Mueller NJ; Garzoni C; Du Pasquier RA; Fux CA; Vernazza P; Bernasconi E; Viscidi R; Battegay M; Hirsch HH; Swiss HIV Cohort Study.. JOURNAL OF VIROLOGY. 2009.

Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study.

Bellini C; Keiser O; Chave JP; Evison J; Fehr J; Kaiser L; Weber R; Vernazza P; Bernasconi E; Telenti A; Cavassini M; Swiss HIV Cohort Study.. HIV medicine. 2009.

Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland.

von Wyl V; Yerly S; Bürgisser P; Klimkait T; Battegay M; Bernasconi E; Cavassini M; Furrer H; Hirschel B; Vernazza PL; Francioli P; Bonhoeffer S; Ledergerber B; Günthard HF; Swiss HIV Cohort Study.. Clinical Infectious Diseases. 2009.

Morbidity and mortality in HIV-infected individuals - a shift towards comorbidities.

Battegay M; Elzi L. Swiss medical weekly. 2009.

Outcomes of early switching from intravenous to oral antibiotics on medical wards.

Mertz D; Koller M; Haller P; Lampert ML; Plagge H; Hug B; Koch G; Battegay M; Flückiger U; Bassetti S. Journal of Antimicrobial Chemotherapy. 2009.

Safety and efficacy of once-daily nevirapine dosing: a multicohort study.

Calmy A; Vallier N; Nguyen A; Lange JM; Battegay M; de Wolf F; Reiss P; Lima VD; Hirschel B; Hogg RS; Yip B; Montaner JS; Wit FW; Swiss HIV Cohort study.; HAART Observational Medical Evaluation and Research Cohort.; Netherlands ATHENA Observational Cohort.. Antiviral therapy. 2009.

Scabies outbreak in an intensive care unit with 1,659 exposed individuals--key factors for controlling the outbreak.

Buehlmann M; Beltraminelli H; Strub C; Bircher A; Jordan X; Battegay M; Itin P; Widmer AF. Infection control and hospital epidemiology. 2009.

Secular trend and risk factors for antimicrobial resistance in Escherichia coli isolates in Switzerland 1997-2007.

Blaettler L; Mertz D; Frei R; Elzi L; Widmer AF; Battegay M; Flückiger U. Infection. 2009.

Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study.

Conen A; Fehr J; Glass TR; Furrer H; Weber R; Vernazza P; Hirschel B; Cavassini M; Bernasconi E; Bucher HC; Battegay M; Swiss HIV Cohort Study.. Antiviral therapy. 2009.

Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV.

Young J; Bucher HC; Guenthard HF; Rickenbach M; Fux CA; Hirschel B; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Swiss HIV Cohort Study.. Antiviral therapy. 2009.

[Commentary on the STROBE statement. A checklist for observational studies improves transparency].

Battegay M. Der Internist. 2008.

11th European AIDS Conference (EACS) - Conference Scene

Battegay,M; Hirschel,B. . 2008.

Antiretroviral therapy of late presenters with advanced HIV disease.

Battegay M; Fehr J; Flückiger U; Elzi L. Journal of Antimicrobial Chemotherapy. 2008.

Appropriateness of antibiotic treatment in intravenous drug users, a retrospective analysis.

Mertz D; Viktorin N; Wolbers M; Laifer G; Leimenstoll B; Fluckiger U; Battegay M. BMC Infectious Diseases. 2008.

Candida krusei--a serious complication in patients with hematological malignancies: successful treatment with caspofungin.

Conen A; Weisser M; Jörg CO; Battegay M; Trampuz A; Frei R; Christen S; Heim D; Gratwohl A; Flückiger U. Transplant infectious disease : an official journal of the Transplantation Society. 2008.

CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.

Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR; Swiss HIV Cohort Study.. Clinical Infectious Diseases. 2008.

Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period.

Conen A; Walti LN; Merlo A; Fluckiger U; Battegay M; Trampuz A. Clinical Infectious Diseases. 2008.

Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV Cohort Study.

Wolbers M; Bucher HC; Furrer H; Rickenbach M; Cavassini M; Weber R; Schmid P; Bernasconi E; Hirschel B; Battegay M; Swiss HIV Cohort Study.. HIV medicine. 2008.

Detection of drug-resistant HIV minorities in clinical specimens and therapy failure.

Louvel S; Battegay M; Vernazza P; Bregenzer T; Klimkait T; Hamy F; Swiss HIV Cohort Study.. HIV medicine. 2008.

Durability and outcome of initial antiretroviral treatments received during 2000--2005 by patients in the Swiss HIV Cohort Study.

Vo TT; Ledergerber B; Keiser O; Hirschel B; Furrer H; Battegay M; Cavassini M; Bernasconi E; Vernazza P; Weber R; Swiss HIV Cohort Study.. The Journal of infectious diseases. 2008.

Effect of antiretroviral therapy on apoptosis markers and morphology in peripheral lymph nodes of HIV-infected individuals.

Ehrhard S; Wernli M; Kaufmann G; Pantaleo G; Rizzardi GP; Gudat F; Erb P; Battegay M. Infection. 2008.

Effects of cognitive behavioral stress management on HIV-1 RNA, CD4 cell counts and psychosocial parameters of HIV-infected persons

Berger S.; Schad T.; Von Wyl V.; Ehlert U.; Zellweger C.; Furrer H.; Regli D.; Vernazza P.; Ledergerber B.; Battegay M.; Weber R.; Gaab J.. AIDS (London, England). 2008.

European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.

Lundgren JD; Battegay M; Behrens G; De Wit S; Guaraldi G; Katlama C; Martinez E; Nair D; Powderly WG; Reiss P; Sutinen J; Vigano A; EACS Executive Committee.. HIV medicine. 2008.

Exposition gegenüber HIV, Hepatitis B und C in Praxis und Spital. Vorbeugung und Post-Expositionsprophylaxe

Gruber,V; Cavassini,M; Battegay,M; Boffi El Amari,E; Tarr,PE. . 2008.

Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.

von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Battegay M; Bernasconi E; Cavassini M; Furrer H; Hirschel B; Vernazza PL; Rickenbach M; Ledergerber B; Günthard HF; Swiss HIV Cohort Study.. Clinical Infectious Diseases. 2008.

Hepatitis with fibrin-ring granulomas.

Khanlari B; Bodmer M; Terracciano L; Heim MH; Fluckiger U; Weisser M. Infection. 2008.

HLA-Bw4 homozygosity is associated with an impaired CD4 T cell recovery after initiation of antiretroviral therapy.

Rauch A; Nolan D; Furrer H; McKinnon E; John M; Mallal S; Gaudieri S; Günthard HF; Schmid P; Battegay M; Hirschel B; Telenti A; James I; Swiss HIV Cohort Study.. Clinical Infectious Diseases. 2008.

Less than 28 days of intravenous antibiotic treatment is sufficient for suppurative thrombophlebitis in injection drug users.

Mertz D; Khanlari B; Viktorin N; Battegay M; Fluckiger U. Clinical Infectious Diseases. 2008.

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.

Antiretroviral Therapy Cohort Collaboration.. Lancet (London, England). 2008.

Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.

Nguyen A; Calmy A; Schiffer V; Bernasconi E; Battegay M; Opravil M; Evison JM; Tarr PE; Schmid P; Perneger T; Hirschel B; Swiss HIV Cohort Study.. HIV medicine. 2008.

Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.

Polesel J; Clifford GM; Rickenbach M; Dal Maso L; Battegay M; Bouchardy C; Furrer H; Hasse B; Levi F; Probst-Hensch NM; Schmid P; Franceschi S; Swiss HIV Cohort Study.. AIDS (London, England). 2008.

Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication.

Ciuffreda D; Comte D; Cavassini M; Giostra E; Bühler L; Perruchoud M; Heim MH; Battegay M; Genné D; Mulhaupt B; Malinverni R; Oneta C; Bernasconi E; Monnat M; Cerny A; Chuard C; Borovicka J; Mentha G; Pascual M; Gonvers JJ; Pantaleo G; Dutoit V. EUROPEAN JOURNAL OF IMMUNOLOGY. 2008.

Response to combination antiretroviral therapy: variation by age - The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group

Sabin, Caroline A.; Smith, Colette J.; Monforte, Antonella d'Arminio; Battegay, Manuel; Gabiano, Clara; Galli, Luisa; Geelen, Sibyl; Gibb, Diana; Guiguet, Marguerite; Judd, Ali; Leport, Catherine; Dabis, Francois; Pantazis, Nikos; Porter, Kholoud; Raffi, Francois; Thorne, Claire; Torti, Carlo; Walker, Sarah; Warszawski, Josiane; Wintergerst, Uwe; Chene, Genevieve; Lundgren, Jens; Weller, Ian; Costagliola, Dominique; Ledergerber, Bruno; Lundgren, Jens; Chene, Genevieve; Touloumi, Giota; Warszawski, Josiane; Meyer, Laurence; Dabis, Francois; Krause, Murielle Mary; Goujard, Cecile; Leport, Catherine; de Wolf, Frank; Reiss, Peter; Porter, Kholoud; Dorrucci, Maria; Sabin, Caroline; Del Amo, Julia; Obel, Niels; Mocroft, Amanda; Kirk, Ole; Staszewski, Schlomo; Perez-Hoyos, Santiago; Almeda, Jesus; Antinori, Andrea; Tovo, Pier-Angelo; Salzberger, Bernd; Fatkenheuer, Gerd; Ramos, Jose; Battegay, Manuel; Mussini, Cristina; Tookey, Pat; Casabona, Jordi; Miro, Jose M.; Castagna, Antonella; de Wit, Stephane; Teira, Ramon; Garrido, Myriam; Dedes, Nikos; Sabin, Caroline; Phillips, Andrew; Furrer, Hansjakob; Egger, Matthias; Newell, Marie-Louise; Sterne, Jonathan; Telenti, Amalio. AIDS (London, England). 2008.

Round-table multidisciplinary counselling of couples with HIV prior to assisted reproduction.

Tschudin S; Steimann S; Bitzer J; Hösli I; Holzgreve W; Elzi L; Klimkait T; Rudin C; Battegay M; De Geyter C. REPRODUCTIVE BIOMEDICINE ONLINE. 2008.

Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients.

Glass TR; De Geest S; Hirschel B; Battegay M; Furrer H; Covassini M; Vernazza PL; Bernasconi E; Rickenboch M; Weber R; Bucher HC; Swiss HIV Cohort Study.. Antiviral therapy. 2008.

Wo HIV-Betreuung in Afrika wirkt

Battegay,M; Stoeckle,M; Tanner,M; Hatz,C. . 2008.

[Diagnostic procedures for patients with community acquired pneumonia].

Flückiger U; Battegay M; Laifer G. Der Internist. 2007.

[Mycobacterium avium pneumonia in an HIV negative patient].

Khanlari B; Burri E; Mihatsch F; Flückiger U; Battegay M. Der Internist. 2007.

CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.

Wolbers M; Battegay M; Hirschel B; Furrer H; Cavassini M; Hasse B; Vernazza PL; Bernasconi E; Kaufmann G; Bucher HC; Swiss HIV Cohort Study.. Antiviral therapy. 2007.

Class of antiretroviral drugs and the risk of myocardial infarction.

DAD Study Group.; Friis-Møller N; Reiss P; Sabin CA; Weber R; Monforte Ad; El-Sadr W; Thiébaut R; De Wit S; Kirk O; Fontas E; Law MG; Phillips A; Lundgren JD. The New England journal of medicine. 2007.

Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.

Raffi F; Battegay M; Rusconi S; Opravil M; Blick G; Steigbigel RT; Kraft M; Neubacher D; Sabo JP. AIDS (London, England). 2007.

Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.

Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M; Swiss HIV Cohort Study.. PLoS One. 2007.

Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study.

Glass TR; Weber R; Vernazza PL; Rickenbach M; Furrer H; Bernasconi E; Cavassini M; Hirschel B; Battegay M; Bucher HC; Swiss HIV Cohort Study.. HIV clinical trials. 2007.

Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types.

von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Battegay M; Furrer H; Telenti A; Hirschel B; Vernazza PL; Bernasconi E; Rickenbach M; Perrin L; Ledergerber B; Günthard HF; Swiss HIV Cohort Study.. ARCHIVES OF INTERNAL MEDICINE. 2007.

Empirical use of antibiotics and adjustment of empirical antibiotic therapies in a university hospital: a prospective observational study.

Mettler J; Simcock M; Sendi P; Widmer AF; Bingisser R; Battegay M; Fluckiger U; Bassetti S. BMC Infectious Diseases. 2007.

Grippe

Hengstler,P; Sponagel,L; Nüesch,R; Battegay,M. . 2007.

HIV in der Schweiz - Welche Rolle spielen die Hausärzte?

Battegay,M. . 2007.

HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts.

Gasser O; Bihl FK; Wolbers M; Loggi E; Steffen I; Hirsch HH; Günthard HF; Walker BD; Brander C; Battegay M; Hess C; Swiss HIV Cohort Study.. PLOS MEDICINE. 2007.

Importance of baseline pognostic factors with increasing time since initiation of highly active antiretroviral therapy. Collaborative analysis of cohorts of HIV-1-infected patients.

The Antiretroviral Therapy Cohort Collaboration: Sterne,JAC; May,M; Sabin,C; Phillips,A; Costagliola,D; Chêne,G; Justice,AC; de Wolf,F; Hogg,R; Battegay,M; Arminio Monforte A,D; Fätkenheuer,G; Staszewski,S; Gill,J; Egger,M. . 2007.

Increased Epstein-Barr virus-specific antibody-levels in HIV-infected individuals developing primary central nervous system lymphoma.

Gasser O; Wolbers M; Steffen I; Hirsch HH; Battegay M; Hess C. AIDS (London, England). 2007.

Infektiologie als Spezialfach

Battegay,M; Flückiger,U. . 2007.

Late presentation of HIV-infected individuals.

Battegay M; Fluckiger U; Hirschel B; Furrer H. Antiviral therapy. 2007.

Lung and infection: Introduction to the topic

Battegay,M; Zabel,P. Der Internist. 2007.

medArt basel '07 Special der Hausarzt Praxis

Mossdorf,E; Battegay,M; Fehr,J. . 2007.

Partial deletion of CYP2B6 owing to unequal crossover with CYP2B7.

Rotger M; Saumoy M; Zhang K; Flepp M; Sahli R; Decosterd L; Telenti A; Swiss HIV Cohort Study.. Pharmacogenetics and Genomics. 2007.

Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.

Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC; Swiss HIV Cohort Study.. AIDS (London, England). 2007.

Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies.

May M; Sterne JA; Sabin C; Costagliola D; Justice AC; Thiébaut R; Gill J; Phillips A; Reiss P; Hogg R; Ledergerber B; D'Arminio Monforte A; Schmeisser N; Staszewski S; Egger M; Antiretroviral Therapy (ART) Cohort Collaboration.. AIDS (London, England). 2007.

Pulmonary infections diagnosed by BAL: a 12-year experience in 1066 immunocompromised patients.

Joos L; Chhajed PN; Wallner J; Battegay M; Steiger J; Gratwohl A; Tamm M. RESPIRATORY MEDICINE. 2007.

TB in a low-incidence country: differences between new immigrants, foreign-born residents and native residents.

Laifer G; Widmer AF; Simcock M; Bassetti S; Trampuz A; Frei R; Tamm M; Battegay M; Fluckiger U. AMERICAN JOURNAL OF MEDICINE. 2007.

Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.

Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT; Swiss HIV Cohort Study.. Antiviral therapy. 2007.

Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.

Huttner AC; Kaufmann GR; Battegay M; Weber R; Opravil M. AIDS (London, England). 2007.

Treatment of an atazanivir associated grade 4 hyperbilirubinaemia with efavirenz.

Kummer O; Mossdorf E; Battegay M; Elzi L; Bodmer M; Krähenbühl S; Haschke M. Gut. 2007.

Two versus three-class antiretroviral therapy in antiretroviral-naive patients in different time periods of the HAART era.

Taffé P; Bucher HC; Flepp M; Battegay M. AIDS (London, England). 2007.

Vertebral osteomyelitis caused by Actinobaculum schaalii: a difficult-to-diagnose and potentially invasive uropathogen.

Haller P; Bruderer T; Schaeren S; Laifer G; Frei R; Battegay M; Flückiger U; Bassetti S. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 2007.

Visceral leishmaniasis: a threat to immunocompromised patients in non-endemic areas?

Weisser M; Khanlari B; Terracciano L; Arber C; Gratwohl A; Bassetti S; Hatz C; Battegay M; Flückiger U. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2007.

When time is more than money: the allocation of time between work and leisure in HIV-infected patients.

Sendi P; Brouwer WB; Bucher HC; Weber R; Battegay M; Swiss HIV Cohort Study.. SOCIAL SCIENCE & MEDICINE. 2007.

["HAART-attack" in young female HIV-patient].

Pittl U; Keller DI; Kaiser CA; Battegay M; Pfisterer ME; Linka A. Der Internist. 2006.

[Check-up-examinations in internal medicine].

Hunziker S; Hengstler P; Zimmerli L; Battegay M; Battegay E. Der Internist. 2006.

[Parasitic diseases].

Battegay M; Mössner J. Der Internist. 2006.

A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?

Simcock M; Sendi P; Ledergerber B; Keller T; Schüpbach J; Battegay M; Günthard HF; Swiss HIV Cohort Study.. Antiviral therapy. 2006.

Antimicrobial prophylaxis to prevent surgical site infections in a rural sub-Saharan hospital.

Fehr J; Hatz C; Soka I; Kibatala P; Urassa H; Battegay M; Jeffrey Z; Smith T; Mshinda H; Frei R; Widmer AF. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2006.

A smoking cessation programme in HIV-infected individuals: a pilot study.

Elzi L; Spoerl D; Voggensperger J; Nicca D; Simcock M; Bucher HC; Spirig R; Battegay M; Swiss HIV Cohort Study.. Antiviral therapy. 2006.

Clinical spectrum of the immune resoration inflammatory syndrome

Battegay,M; Drechsler,H. . 2006.

Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study.

Glass TR; De Geest S; Weber R; Vernazza PL; Rickenbach M; Furrer H; Bernasconi E; Cavassini M; Hirschel B; Battegay M; Bucher HC. Journal of Acquired Immune Deficiency Syndromes. 2006.

Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study.

Zinkernagel AS; von Wyl V; Ledergerber B; Rickenbach M; Furrer H; Battegay M; Hirschel B; Tarr PE; Opravil M; Bernasconi E; Schmid P; Weber R; Swiss HIV Cohort Study.. Antiviral therapy. 2006.

Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection.

Gaudieri S; Rauch A; Park LP; Freitas E; Herrmann S; Jeffrey G; Cheng W; Pfafferott K; Naidoo K; Chapman R; Battegay M; Weber R; Telenti A; Furrer H; James I; Lucas M; Mallal SA. JOURNAL OF VIROLOGY. 2006.

Grippe

Battegay,M. . 2006.

Hearing loss after discontinuing secondary prophylaxis for cryptococcal meningitis: relapse or immune reconstitution?

Khanna N; Nüesch R; Buitrago-Tellez C; Battegay M; Hirsch HH. Infection. 2006.

Immunological recovery and antiretroviral therapy in HIV-1 infection.

Battegay M; Nüesch R; Hirschel B; Kaufmann GR. The Lancet. Infectious diseases. 2006.

Moving up from 3 by 5.

Stoeckle M; Mchomvu R; Hatz C; Battegay M; Aris EA; Mshinda H; Tanner M. The Lancet. Infectious diseases. 2006.

Once-daily directly observed therapy lopinavir/ritonavir plus indinavir as a protease inhibitor-only salvage therapy in heavily pretreated HIV-1-infected patients: a pilot study.

Elzi L; Hirsch HH; Battegay M. AIDS (London, England). 2006.

Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study.

Glass TR; Ungsedhapand C; Wolbers M; Weber R; Vernazza PL; Rickenbach M; Furrer H; Bernasconi E; Cavassini M; Hirschel B; Battegay M; Bucher HC; Swiss HIV Cohort Study.. HIV medicine. 2006.

[Clinical study of infectious diseases. An interdisciplinary challenge in medicine].

Flückiger U; Battegay M. Der Internist. 2005.

[Ready for antiretroviral therapy? Therapy decision making experiences of persons living with HIV].

Nicca D; Fehr J; Battegay M; Spirig R. Pflege. 2005.

[Status febrilis and unconsciousness].

Sawatzki M; Hatz C; Buser A; Battegay M. Der Internist. 2005.

[The 3' by 5' WHO/UNAIDS initiative--can 3 million people obtain HIV therapies by the end of 2005].

Battegay M; Hatz Ch; Stoeckle M; Tanner M. Praxis. 2005.

[The value of clinical infectology].

Battegay M; Flückiger U. Der Internist. 2005.

Allgemeine Aspekte zu Diagnose und Differenzialdiagnose

Battegay,M; Martina,B; Battegay,E. . 2005.

Allgemeine Aspekte zur Differentialdiagnose

Battegay,M; Martina,B; Battegay,E. . 2005.

Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.

Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC. Antiviral therapy. 2005.

Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.

Kaufmann GR; Furrer H; Ledergerber B; Perrin L; Opravil M; Vernazza P; Cavassini M; Bernasconi E; Rickenbach M; Hirschel B; Battegay M; Swiss HIV Cohort Study.. Clinical Infectious Diseases. 2005.

Contrary to HIV, hepatitis C virus is not associated with erythrocytes in vivo.

Sadallah S; Heim M; Hess C; Klimkait T; Battegay M; Schifferli JA. Journal of hepatology. 2005.

Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir.

Karrer U; Ledergerber B; Furrer H; Elzi L; Battegay M; Cavassini M; Gayet-Ageron A; Hirschel B; Schmid P; Russotti M; Weber R; Speck RF; Swiss HIV Cohort Study.. AIDS (London, England). 2005.

Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care.

Hirsch HH; Drechsler H; Holbro A; Hamy F; Sendi P; Petrovic K; Klimkait T; Battegay M. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 2005.

Haut und äusseres Erscheinungsbild

Lautenschlager,S; Battegay,M; Spinas,GA. . 2005.

HIV-1 p24 may persist during long-term highly active antiretroviral therapy, increases little during short treatment breaks, and its rebound after treatment stop correlates with CD4(+) T cell loss.

Schüpbach J; Günthard H; Joos B; Fischer M; Böni J; Tomasik Z; Yerly S; Perrin L; Battegay M; Furrer H; Vernazza P; Bernasconi E; Hirschel B; Swiss HIV Cohort Study.. Journal of Acquired Immune Deficiency Syndromes. 2005.

HIV und AIDS

Flueckiger,U; Battegay,M. . 2005.

Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.

Kinloch-de Loes S; Hoen B; Smith DE; Autran B; Lampe FC; Phillips AN; Goh LE; Andersson J; Tsoukas C; Sonnerborg A; Tambussi G; Girard PM; Bloch M; Battegay M; Carter N; El Habib R; Theofan G; Cooper DA; Perrin L; QUEST Study Group.. The Journal of infectious diseases. 2005.

Lipid profiles for antiretroviral-naive patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort study.

Young J; Weber R; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC. Antiviral therapy. 2005.

Management of HIV immune reconstitution syndrome

Drechsler,H; Kaufmann,G; Hirsch,HH; Battegay,M. . 2005.

Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders.

Tarr PE; Taffé P; Bleiber G; Furrer H; Rotger M; Martinez R; Hirschel B; Battegay M; Weber R; Vernazza P; Bernasconi E; Darioli R; Rickenbach M; Ledergerber B; Telenti A; Swiss HIV Cohort Study.. The Journal of infectious diseases. 2005.

Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients.

Alberti A; Clumeck N; Collins S; Gerlich W; Lundgren J; Palù G; Reiss P; Thiebaut R; Weiland O; Yazdanpanah Y; Zeuzem S; ECC Jury.. Journal of hepatology. 2005.

Starting or changing therapy - a prospective study exploring antiretroviral decision-making.

Fehr JS; Nicca D; Sendi P; Wolf E; Wagels T; Kiss A; Bregenzer T; Vernazza P; Jäger H; Spirig R; Battegay M; Swiss HIV Cohort Study.. Infection. 2005.

Symptom management in HIV/AIDS: advancing the conceptualization.

Spirig R; Moody K; Battegay M; De Geest S. ADVANCES IN NURSING SCIENCE. 2005.

[Primary HIV infection].

Battegay M; Hirschel B. Therapeutische Umschau. 2004.

[Travel in a smaller world].

Battegay M; Manns MP. Der Internist. 2004.

Acute renal failure on immune reconstitution in an HIV-positive patient with miliary tuberculosis.

Jehle AW; Khanna N; Sigle JP; Glatz-Krieger K; Battegay M; Steiger J; Dickenmann M; Hirsch HH. Clinical Infectious Diseases. 2004.

All cause mortality in the Swiss HIV Cohort Study from 1990 to 2001 in comparison with the Swiss population.

Keiser O; Taffé P; Zwahlen M; Battegay M; Bernasconi E; Weber R; Rickenbach M; Swiss HIV Cohort Study.. AIDS (London, England). 2004.

Carriage of Staphylococcus aureus among injection drug users: lower prevalence in an injection heroin maintenance program than in an oral methadone program.

Bassetti S; Wolfisberg L; Jaussi B; Frei R; Kuntze MF; Battegay M; Widmer AF. Infection control and hospital epidemiology. 2004.

Chest pain after travel to the tropics.

Elzi L; Decker M; Battegay M; Rutishauser J; Blum J. Lancet (London, England). 2004.

Cutaneous plasmablastic lymphoma in an HIV-positive male: an unrecognized cutaneous manifestation.

Häusermann P; Khanna N; Buess M; Itin PH; Battegay M; Dirnhofer S; Buechner SA. Dermatology (Basel, Switzerland). 2004.

Epstein-Barr virus load correlating with clinical manifestation and treatment response in a patient with angioimmunoblastic T-cell lymphoma.

Battegay M; Berger C; Rochlitz C; Hurwitz N; Hirsch HH; De Geyter C; Haque T; Nadal D. Antiviral therapy. 2004.

Gynecomastia and potent antiretroviral therapy.

Strub C; Kaufmann GR; Flepp M; Egger M; Kahlert C; Cavassini M; Battegay M; Swiss HIV Cohort Study.. AIDS (London, England). 2004.

Herausforderungen bei der HIV-Langzeitbetreuung. in: Jäger H (Hrsg) AIDS und HIV-Infektionen. Diagnostik - Klinik - Behandlung. Handbuch und Atlas für Klinik und Praxis

Battegay,M; Furrer,H. . 2004.

Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point.

Trkola A; Kuster H; Leemann C; Oxenius A; Fagard C; Furrer H; Battegay M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Bonhoeffer S; Günthard HF; Swiss HIV Cohort Study.. Blood. 2004.

Immune reconstitution in HIV-infected patients.

Hirsch HH; Kaufmann G; Sendi P; Battegay M. Clinical Infectious Diseases. 2004.

Infrequent transmission of HIV-1 drug-resistant variants.

Yerly S; Jost S; Telenti A; Flepp M; Kaiser L; Chave JP; Vernazza P; Battegay M; Furrer H; Chanzy B; Burgisser P; Rickenbach M; Gebhardt M; Bernard MC; Perneger T; Hirschel B; Perrin L; Swiss HIV Cohort Study.. Antiviral therapy. 2004.

Intranasal influenza vaccine in a working population.

Sendi P; Locher R; Bucheli B; Battegay M. Clinical Infectious Diseases. 2004.

Is unsafe sexual behaviour increasing among HIV-infected individuals?

Glass TR; Young J; Vernazza PL; Rickenbach M; Weber R; Cavassini M; Hirschel B; Battegay M; Bucher HC; Swiss HIV Cohort Study.. AIDS (London, England). 2004.

Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection.

Kaufmann GR; Khanna N; Weber R; Perrin L; Furrer H; Cavassini M; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Hirschel B; Battegay M; Swiss HIV Cohort Study.. Antiviral therapy. 2004.

Optimising the performance of an outpatient setting.

Sendi P; Al MJ; Battegay M. Swiss medical weekly. 2004.

Persistent apoptosis in HIV-1-infected individuals receiving potent antiretroviral therapy is associated with poor recovery of CD4 T lymphocytes.

Hansjee N; Kaufmann GR; Strub C; Weber R; Battegay M; Erb P; Swiss HIV Cohort Study.. Journal of Acquired Immune Deficiency Syndromes. 2004.

Predictive value of adherence in patients starting highly active antiretroviral treatment for HIV infection.

Wagels T; Amiet R; Battegay M; Guex AC; Opravil M; Vernazza PL; Swiss HIV Cohort Study Group.. Swiss medical weekly. 2004.

Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes.

Ledergerber B; Lundgren JD; Walker AS; Sabin C; Justice A; Reiss P; Mussini C; Wit F; d'Arminio Monforte A; Weber R; Fusco G; Staszewski S; Law M; Hogg R; Lampe F; Gill MJ; Castelli F; Phillips AN; PLATO Collaboration.. Lancet (London, England). 2004.

Productivity costs and determinants of productivity in HIV-infected patients.

Sendi P; Schellenberg F; Ungsedhapand C; Kaufmann GR; Bucher HC; Weber R; Battegay M; Swiss HIV Cohort Study.. CLINICAL THERAPEUTICS. 2004.

Protease inhibitor-sparing simplified maintenance therapy: a need for perspective.

Bucher HC; Young J; Battegay M. Journal of Antimicrobial Chemotherapy. 2004.

Reply to Intranasal Versus Injectable Influenza Vaccine

Sendi,P; Locher,R; Battegay,M. Clinical Infectious Diseases. 2004.

Schwerpunktheft Reisemedizin

Battegay,M (Hrsg); Manns,MP (Hrsg). . 2004.

Sexual risk behavior in HIV-infected injection drug users.

Battegay M; Bucher HC; Vernazza P. Clinical Infectious Diseases. 2004.

Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study.

Young J; De Geest S; Spirig R; Flepp M; Rickenbach M; Furrer H; Bernasconi E; Hirschel B; Telenti A; Vernazza P; Battegay M; Bucher HC; Swiss HIV Cohort Study Group.. BMJ (Clinical research ed.). 2004.

Staphylococcus aureus infections in injection drug users: risk factors and prevention strategies.

Bassetti S; Battegay M. Infection. 2004.

The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study.

Felley C; Morris MA; Wonkam A; Hirschel B; Flepp M; Wolf K; Furrer H; Battegay M; Bernasconi E; Telenti A; Frossard JL. AIDS (London, England). 2004.

[Challenges in HIV long-term care].

Furrer H; Battegay M; Spirig R; Flepp M; Swiss HIV Cohort Study Group.. Deutsche medizinische Wochenschrift (1946). 2003.

[HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia].

Hirsch HH; Battegay M. Deutsche medizinische Wochenschrift (1946). 2003.

[Smoking cessation for HIV infected patients].

Voggensperger J; Nicca D; Battegay M; Zellweger JP; Spirig R. Pflege. 2003.

[Therapy of severe fungal infections].

Battegay M; Flückiger U. Der Internist. 2003.

A prospective trial of structured treatment interruptions in human immunodeficiency virus infection.

Fagard C; Oxenius A; Günthard H; Garcia F; Le Braz M; Mestre G; Battegay M; Furrer H; Vernazza P; Bernasconi E; Telenti A; Weber R; Leduc D; Yerly S; Price D; Dawson SJ; Klimkait T; Perneger TV; McLean A; Clotet B; Gatell JM; Perrin L; Plana M; Phillips R; Hirschel B; Swiss HIV Cohort Study.. ARCHIVES OF INTERNAL MEDICINE. 2003.

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.

Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M; Swiss HIV Cohort Study Group.. ARCHIVES OF INTERNAL MEDICINE. 2003.

Comment letter on reply on article #124

Wolf,K; Battegay,M. . 2003.

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

Lazzarin A; Clotet B; Cooper D; Reynes J; Arastéh K; Nelson M; Katlama C; Stellbrink HJ; Delfraissy JF; Lange J; Huson L; DeMasi R; Wat C; Delehanty J; Drobnes C; Salgo M; TORO 2 Study Group.. The New England journal of medicine. 2003.

Enfuvirtide

Battegay,M. . 2003.

Evaluation of unstructured medical school examinations: prospective observational study.

Zeller A; Battegay M; Gyr N; Battegay E. Swiss medical weekly. 2003.

High risk behaviour and fertility desires among heterosexual HIV-positive patients with a serodiscordant partner--two challenging issues.

Panozzo L; Battegay M; Friedl A; Vernazza PL; Swiss Cohort Study.. Swiss medical weekly. 2003.

HIV Testung während der Schwangerschaft

Fachkommission,Klinik; Therapie,HIV/AIDS. . 2003.

Intravenous opiate maintenance in a cohort of injecting drug addicts.

Sendi P; Hoffmann M; Bucher HC; Erb P; Haller P; Gyr N; Battegay M. DRUG AND ALCOHOL DEPENDENCE. 2003.

Mann 40+; Kompaktwissen Gesundheit

Gasser,T; Battegay,E; Elke,B. . 2003.

Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients.

Bucher HC; Kofler A; Nüesch R; Young J; Battegay M; Opravil M. AIDS (London, England). 2003.

Migrants from Sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival.

Staehelin C; Rickenbach M; Low N; Egger M; Ledergerber B; Hirschel B; D'Acremont V; Battegay M; Wagels T; Bernasconi E; Kopp C; Furrer H; Swiss HIV Cohort Study.. AIDS (London, England). 2003.

Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population.

Jaggy C; von Overbeck J; Ledergerber B; Schwarz C; Egger M; Rickenbach M; Furrer HJ; Telenti A; Battegay M; Flepp M; Vernazza P; Bernasconi E; Hirschel B; Swiss HIV Cohort Study.. Lancet (London, England). 2003.

[Developing and establishing an expanded and more comprehensive HIV/AIDS nursing practice].

Spirig R; Nicca D; Werder V; Voggensperger J; Unger M; Bischofberger I; Kesselring A; Battegay M; De Geest S. Pflege. 2002.

[Mansonella perstans filariasis after stay in Cameroon. A 19-year-old patient born in Cameroon, in Switzerland for the last 10 years].

Kiefer G; Battegay M; Gyr N; Hatz C. Praxis. 2002.

Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV Cohort Study.

Bernasconi E; Boubaker K; Junghans C; Flepp M; Furrer HJ; Haensel A; Hirschel B; Boggian K; Chave JP; Opravil M; Weber R; Rickenbach M; Telenti A; Swiss HIV Cohort Study.. Journal of Acquired Immune Deficiency Syndromes. 2002.

Aktualisierte Empfehlungen 2002 zur beruflichen Exposition mit Blut oder biologischen Flüssigkeiten

Fachkommission,Klinik; Therapie,HIV/AIDS. . 2002.

Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1.

Wolf K; Tsakiris DA; Weber R; Erb P; Battegay M; Swiss HIV Cohort Study.. The Journal of infectious diseases. 2002.

Anxiety in health care workers after exposure to potentially HIV-contaminated blood or body fluids.

Meienberg F; Bucher HC; Sponagel L; Zinkernagel C; Gyr N; Battegay M. Swiss medical weekly. 2002.

A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection.

Opravil M; Hirschel B; Lazzarin A; Furrer H; Chave JP; Yerly S; Bisset LR; Fischer M; Vernazza P; Bernasconi E; Battegay M; Ledergerber B; Günthard H; Howe C; Weber R; Perrin L; Swiss HIV Cohort Study.. The Journal of infectious diseases. 2002.

Association of a pool of HIV-1 with erythrocytes in vivo: a cohort study.

Hess C; Klimkait T; Schlapbach L; Del Zenero V; Sadallah S; Horakova E; Balestra G; Werder V; Schaefer C; Battegay M; Schifferli JA. Lancet (London, England). 2002.

Die Langzeitbetreuung HIV-infizierter Patientinnen und Patientnen. Eine Herausforderung für die Medizin

Battegay,M; Furrer,H. . 2002.

Disappearance of an intracerebral arteriovenous malformation in an HIV-infected patient after initiation of HAART.

Wolf K; Kirsch EC; Sponagel L; Rüfenacht DA; Battegay M. Infection. 2002.

Effect of highly active antiretroviral therapy on hospitalization characteristics of HIV-infected patients.

Nuesch R; Geigy N; Schaedler E; Battegay M. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 2002.

Evidence for prevention and screening: recommendations in adults.

Hengstler P; Battegay E; Cornuz J; Bucher H; Battegay M. Swiss medical weekly. 2002.

Impact of protease polymorphisms and viral fitness on human immunodeficiency virus (HIV) type 1 viremia in untreated HIV-1 infection.

Märki Y; Kaufmann GR; Battegay M; Klimkait T; Swiss HIV Cohort Study.. The Journal of infectious diseases. 2002.

Infections requiring hospitalization of injection drug users who participated in an injection opiate maintenance program.

Bassetti S; Hoffmann M; Bucher HC; Fluckiger U; Battegay M. Clinical Infectious Diseases. 2002.

Inflammatory bowel perforation during immune restoration after one year of antiretroviral and antituberculous therapy in an HIV-1-infected patient: report of a case.

Guex AC; Bucher HC; Demartines N; Flückiger U; Battegay M. Diseases of the Colon and Rectum. 2002.

Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.

Greub,G; Cozzi-Lepri,A; Ledergerber,B; Staszewski,S; Perrin,L; Miller,V; Francioli,P; Furrer,H; Battegay,M; Vernazza,P; Bernasconi,E; Guenthard,HF; Hirschel,B; Phillips,AN; Telenti,A. AIDS (London, England). 2002.

Lipodystrophie und Dyslipidämie: Auftreten, Riskofaktoren und Mechanismen.

Battegay,M; Hirsch,HH. . 2002.

Lipodystrophy and Dyslipidaemia: Presentation, risk factors and mechanisms. AIDS - Die Auseinandersetzung geht weiter.

Battegay,M; Hirsch,HH. . 2002.

Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management.

Hirsch HH; Battegay M. Infection. 2002.

Notfallsituationen bei HIV-infizierten Patienten

Bassetti,S; Zimmerli,W; Battegay,M. . 2002.

Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.

Tilling R; Kinloch S; Goh LE; Cooper D; Perrin L; Lampe F; Zaunders J; Hoen B; Tsoukas C; Andersson J; Janossy G; Quest Study Group.. AIDS (London, England). 2002.

Potential benefit and limitations of a broad access to potent antiretroviral therapy in developing countries.

Kaufmann GR; Smith D; Bucher HC; Phanuphak P; Sendi PP; Mbidde EK; Cooper DA; Battegay M. EXPERT OPINION ON INVESTIGATIONAL DRUGS. 2002.

Prévention primaire et dépistage chez l'adulte: quelles sont les priorités en 2002?

Cornuz,J; Gervasoni,JP; Hengstler,P; Battegay,M; and Battegay,E. . 2002.

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Egger M; May M; Chêne G; Phillips AN; Ledergerber B; Dabis F; Costagliola D; D'Arminio Monforte A; de Wolf F; Reiss P; Lundgren JD; Justice AC; Staszewski S; Leport C; Hogg RS; Sabin CA; Gill MJ; Salzberger B; Sterne JA; ART Cohort Collaboration.. Lancet (London, England). 2002.

Ritonavir plus saquinavir versus single protease inhibitor therapy in protease inhibitor-naive HIV-infected patients: the Swiss HIV Cohort Study.

Bucher HC; Bichsel M; Taffé P; Furrer H; Telenti A; Hirschel B; Weber R; Bernasconi E; Vernazza P; Minder C; Battegay M; Swiss HIV Cohort Study.. HIV medicine. 2002.

Therapeutic profile of enfuvertide in treatment-experienced patients

Battegay,M. . 2002.

[Anemia, neutropenia and thrombocytopenia: hematological findings and HIV].

Wolf K; Tichelli A; Battegay M. Praxis. 2001.

[Generalized lymphadenopathy in a 43-year-old patient].

Stöckli R; Battegay M. Praxis. 2001.

[Hospitalizations in a cohort of 175 severely drug-addicted patients of a medically managed opiate withdrawal project].

Hoffmann M; Haller P; Bucher HC; Gyr N; Battegay M. Praxis. 2001.

[Vaccinations in adults].

Hengstler P; Battegay M. Praxis. 2001.

Acute HIV infection: impact on the spread of HIV and transmission of drug resistance.

Yerly S; Vora S; Rizzardi P; Chave JP; Vernazza PL; Flepp M; Telenti A; Battegay M; Veuthey AL; Bru JP; Rickenbach M; Hirschel B; Perrin L; Swiss HIV Cohort Study.. AIDS (London, England). 2001.

A randomised trial with methadone, morphine and heroin in the treatment of opiate dependence

Ladewig,D; Hug,I; Stohler,R; Battegay,M; Gyr,K; Erb,P; Rohr,H; Uchtenhagen,A. . 2001.

A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia.

Miserez AR; Muller PY; Barella L; Schwietert M; Erb P; Vernazza PL; Battegay M; Swiss HIV Cohort Study.. AIDS (London, England). 2001.

Combined therapy with saquinavir, ritonavir and stavudine in moderately to severely immunosuppressed HIV-infected protease inhibitor-naive patients.

Battegay M; Vernazza PL; Bernasconi E; Flepp M; Sendi P; Erb P; Malinverni R; Jaccard C; Morgenthaler S; Bedoucha V; Hirschel B; Swiss HIV Cohort Study.. HIV medicine. 2001.

Critical issues of HIV treatment in the era of highly active antiretroviral therapy.

Battegay M. EXPERT OPINION ON INVESTIGATIONAL DRUGS. 2001.

Die Schweizerische HIV-Kohortenstudie: Bilanz und Perspektiven

Francioli,P; Battegay,M; Rickenbach,M. . 2001.

Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.

Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD; Eight European Study Groups.. The New England journal of medicine. 2001.

Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection.

Sendi P; Palmer AJ; Gafni A; Battegay M. PHARMACOECONOMICS. 2001.

Importance of mental health assessment in HIV-infected outpatients.

Zinkernagel C; Taffé P; Rickenbach M; Amiet R; Ledergerber B; Volkart AC; Rauchfleisch U; Kiss A; Werder V; Vernazza P; Battegay M; Swiss HIV Cohort Study.. Journal of Acquired Immune Deficiency Syndromes. 2001.

Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infection.

Bisset LR; Cone RW; Fischer M; Battegay M; Vernazza PL; Dubs RW; Weber R; Grob PJ; Opravil M; Swiss HIV Cohort Study.. Journal of Acquired Immune Deficiency Syndromes. 2001.

Onset and pattern of substance use in intravenous drug users of an opiate maintenance program.

Zinkernagel C; Naef MR; Bucher HC; Ladewig D; Gyr N; Battegay M. DRUG AND ALCOHOL DEPENDENCE. 2001.

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study.

Fellay J; Boubaker K; Ledergerber B; Bernasconi E; Furrer H; Battegay M; Hirschel B; Vernazza P; Francioli P; Greub G; Flepp M; Telenti A; Swiss HIV Cohort Study.. Lancet (London, England). 2001.

Reasons for discontinuation of first highly active antiretroviral therapy in a cohort of proteinase inhibitor-naive HIV-infected patients.

Hänsel A; Bucher HC; Nüesch R; Battegay M. Journal of Acquired Immune Deficiency Syndromes. 2001.

Sexual transmission during the incubation period of primary HIV infection.

Pilcher CD; Eron JJ Jr; Vemazza PL; Battegay M; Harr T; Yerly S; Vom S; Perrin L. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2001.

Simultaneous occurrence of 2 HIV-related immunereconstitution diseases after initiation of highly active antiretroviral therapy.

Legendre U; Battegay M; Nuttli I; Dalquen P; Nuesch R. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2001.

Successful treatment of hepatitis B associated polyarteritis using lamivudine as sole therapeutic agent

Maclachlan,D; Battegay,M; Jacob,AL; Tyndall,A. . 2001.

The use of lipid-lowering agents in HIV-infected patients.

Meienberg F; Battegay E; Bucher HC; Battegay M. J HIV Ther. 2001.

[Neurological complications of HIV infection. Review: new diagnostic, therapeutic and prognostic aspects].

Radziwill AJ; Kappos L; Battegay M; Steck AJ. Schweizerische Medizinische Wochenschrift. 2000.

Access to antiretroviral therapy.

Bassetti S; Battegay M; Sudre P. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2000.

Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988-2000.

Sudre P; Rickenbach M; Taffé P; Janin P; Volkart AC; Francioli P; Swiss HIV Cohort Study.. Schweizerische Medizinische Wochenschrift. 2000.

Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.

Greub G; Ledergerber B; Battegay M; Grob P; Perrin L; Furrer H; Burgisser P; Erb P; Boggian K; Piffaretti JC; Hirschel B; Janin P; Francioli P; Flepp M; Telenti A. Lancet (London, England). 2000.

Combination antiretroviral therapy and duration of pregnancy.

European Collaborative Study.; Swiss Mother and Child HIV Cohort Study.. AIDS (London, England). 2000.

Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study.

Erb P; Battegay M; Zimmerli W; Rickenbach M; Egger M. ARCHIVES OF INTERNAL MEDICINE. 2000.

Empfehlungen zur antiretrovirale HIV-Therapie 2001

Subkommission; Klinik; (SKK); der; Eidg; Kommission; für; AIDS,Fragen; (EKAF). . 2000.

HIV-1-Resistenz gegen antiretrovirale Substanzen in der Schweiz

Subkommission; Klinik; (SKK); der; Eidg; Kommission; für; AIDS,Fragen; (EKAF). . 2000.

Human immunodeficiency and hepatitis C virus coinfection influenced by interferon-gamma.

Battegay M; Holdener M; Naef M; Wernli M. IMMUNOLOGY LETTERS. 2000.

Mycobacterium kansasii abscess of the chest wall after drainage of bacterial empyema.

Tietz A; Tamm M; Battegay M. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 2000.

Nutritional supplements combined with dietary counselling diminish whole body protein catabolism in HIV-infected patients.

Berneis K; Battegay M; Bassetti S; Nuesch R; Leisibach A; Bilz S; Keller U. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2000.

Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.

Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M. AIDS (London, England). 2000.

Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.

Smith D; Berrey MM; Robertson M; Mehrotra D; Markowitz M; Perrin L; Clumeck N; Lazzarin A; Burckhardt B; Weber R; Corey L; Cooper DA. The Journal of infectious diseases. 2000.

[Focal mycobacterial lymphadenitis after starting highly active antiretroviral therapy].

Schwietert M; Battegay M. Deutsche medizinische Wochenschrift (1946). 1999.

[HIV post-exposure prophylaxis after sexual risk contact].

Battegay M; Zimmerli W. Schweizerische Medizinische Wochenschrift. 1999.

[Setting and pulling of a port needle. Fachgruppe Onkologie im DBfK, Landesrerband Bayern].

. Pflege Aktuell. 1999.

AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Ledergerber B; Egger M; Erard V; Weber R; Hirschel B; Furrer H; Battegay M; Vernazza P; Bernasconi E; Opravil M; Kaufmann D; Sudre P; Francioli P; Telenti A. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 1999.

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study.

Ledergerber B; Egger M; Opravil M; Telenti A; Hirschel B; Battegay M; Vernazza P; Sudre P; Flepp M; Furrer H; Francioli P; Weber R. Lancet (London, England). 1999.

Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study.

Sendi PP; Bucher HC; Harr T; Craig BA; Schwietert M; Pfluger D; Gafni A; Battegay M. AIDS (London, England). 1999.

Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.

Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R. The New England journal of medicine. 1999.

Downregulation of Bcl-2, but not of Bax or Bcl-x, is associated with T lymphocyte apoptosis in HIV infection and restored by antiretroviral therapy or by interleukin 2.

Regamey N; Harr T; Battegay M; Erb P. AIDS RESEARCH AND HUMAN RETROVIRUSES. 1999.

Ein Silberstreifen am Horizont. Gesprächsrunde über AIDS

Battegay,M; Mascarin,R; Pärli,K; Gelzer,D. . 1999.

Estimating AIDS-free survival in a severely immunosuppressed asymptomatic HIV-infected population in the era of antiretroviral triple combination therapy. Swiss HIV Cohort Study.

Sendi PP; Bucher HC; Craig BA; Pfluger D; Battegay M. J ACQ IMMUN DEF SYND. 1999.

Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study.

Bürgisser P; Hammann C; Kaufmann D; Battegay M; Rutschmann OT. Clinical and experimental immunology. 1999.

General and specific immunosuppression caused by antiviral T-cell responses.

Zinkernagel RM; Planz O; Ehl S; Battegay M; Odermatt B; Klenerman P; Hengartner H. IMMUNOLOGICAL REVIEWS. 1999.

HIV-Infektion und AIDS

Battegay,M; Hirschel,B. . 1999.

HIV update 1999

Schwietert M.; Battegay M.. Therapiewoche. 1999.

Impfstoffe gegen HIV - Realität oder Hoffnung

Battegay,M. . 1999.

Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials.

Bucher HC; Griffith LE; Guyatt GH; Sudre P; Naef M; Sendi P; Battegay M. AIDS (London, England). 1999.

Is there a relation between risk groups or initial CD4 T cell counts and prevalence of seborrheic dermatitis in HIV-infected patients?

Schaub NA; Drewe J; Sponagel L; Gilli L; Courvoisier S; Gyr N; Rufli T; Battegay M; Itin P. Dermatology (Basel, Switzerland). 1999.

Können HIV-infizierte Erwachsene die primäre Prophylaxe gegen Pneumocystis-carinii-Pneumonie absetzen?

Subkommission; Klinik; (SKK); der; Eidg; Kommission; für; AIDS,Fragen; (EKAF). . 1999.

Neuerungen und Ergänzungen zum HIV-Testkonzept 1998

Subkommission,Serologie; Immunologie; Virologie,(SIV); Subkommission,Klinik (SKK) der Eidg.Kommission für AIDS-Fragen (EKAF). . 1999.

Notfallsituationen bei HIV-infizierten Patienten

Burckhardt,B; Zimmerli,W; Battegay,M. . 1999.

Präventionsempfehlungen zur Reduktion des HIV-Übertragunsrisikos bei orogenitalen Sexualpraktiken behalten ihre Gültigkeit

Subkommission; Klinik; (SKK); der; Eidg; Kommission; für; AIDS,Fragen; (EKAF). . 1999.

Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study.

Zinkernagel C; Ledergerber B; Battegay M; Cone RW; Vernazza P; Hirschel B; Opravil M. AIDS (London, England). 1999.

Rare AIDS-defining diseases in the Swiss HIV Cohort Study.

Burckhardt B; Sendi P; Pfluger D; Zimmerli W; Nüesch R; Bucher HC; Drewe J; Gyr N; Battegay M. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 1999.

Salvage treatment against human immunodeficiency virus.

Battegay M; Harr T; Sponagel L. ANNALS OF MEDICINE. 1999.

Treatment for human immunodeficiency virus with indinavir may cause relevant urological side-effects, effectively treatable by rehydration.

Hug B; Naef M; Bucher HC; Sponagel L; Lehmann K; Battegay M. BJU international. 1999.

Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study.

Bassetti S; Battegay M; Furrer H; Rickenbach M; Flepp M; Kaiser L; Telenti A; Vernazza PL; Bernasconi E; Sudre P. Journal of Acquired Immune Deficiency Syndromes. 1999.

[Anti-retroviral therapy and antiepileptics. Case report and discussion].

Hug B; Kaeser YA; Haefeli WE; Battegay M. Schweizerische Medizinische Wochenschrift. 1998.

[Clinically significant drug interactions in HIV-infected patients].

Weisser M; Battegay M. Therapeutische Umschau. 1998.

[Emergencies in HIV infection].

Burckhardt B; Battegay M. Therapeutische Umschau. 1998.

[Quality aspects in internal medicine--from anamnesis to meta-analysis].

Battegay M; Martina B; Bucheli B; Wagner P; Battegay E; Bucher HC. Praxis. 1998.

Antiretrovirale Behandlung während der Schwangerschaft

Subkommission; Klinik; (SKK); der; Eidg; Kommission; für; AIDS,Fragen; (EKAF). . 1998.

Antiretrovirale HIV-Therapie

Subkommission; Klinik; (SKK); der; Eidg; Kommission; für; AIDS,Fragen; (EKAF). . 1998.

Does pregnancy influence the course of HIV infection? Evidence from two large Swiss cohort studies.

Weisser M; Rudin C; Battegay M; Pfluger D; Kully C; Egger M. J ACQ IMMUN DEF SYND. 1998.

Early participation in an HIV cohort study slows disease progression and improves survival. The Swiss HIV Cohort Study.

Battegay M; Wirz M; Steuerwald MH; Egger M. Journal of internal medicine. 1998.

Early results of dual PI therapy in PI-naive and PI-experienced individuals

Battegay,M. . 1998.

Epidemiologie von Hautkrankheiten bei HIV-Infizierten: Die Basler Kohortenstudie

Itin,P; Schaub,N; Courvoisier,S; Gyr,N; Tietz,A; Rufli,T; Battegay,M. . 1998.

Genotype distribution of hepatitis C virus infection in Greece: correlation with different risk factors and response to interferon therapy.

Diamantis I; Vafiadis I; Voskaridou E; Dellatetsima J; Jäggi N; Gyr K; Battegay M. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY. 1998.

Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C.

Battegay M; Naef M; Bucher HC. The New England journal of medicine. 1998.

Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study.

Bisset LR; Cone RW; Huber W; Battegay M; Vernazza PL; Weber R; Grob PJ; Opravil M. AIDS (London, England). 1998.

Human immunodeficiency virus mutation and changes in CD4 T-cell levels during antiretroviral therapy.

Battegay M. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 1998.

Impact des nouvelles associations thérapeutiques sur l'incidence du SIDA dans l'étude Suisse de Cohorte VIH

Egger,M; Sudre,P; Battegay,M; Wirz,M; Rickenbach,M; Ledergerber,B. . 1998.

Interferon-alpha activates signal transducers and activators of transcription 5 and 6 in Daudi cells.

Fasler-Kan E; Pansky A; Wiederkehr M; Battegay M; Heim MH. EUR J BIOCHEM. 1998.

Is CD95 or CD26 expression on T-cells a marker for HIV non- or slow-progressor status?

Harr T.; Von Overbeck J.; Battegay M.; Erb P.; Bürgisser Ph.; Fierz W.; Flepp M.; Francioli P.; Grob P.; Hirschel B.; Ledergerber B.; Lüthy R.; Malinverni R.; Matter L.; Opravil M.; Perrin L.; Pichler W.; Rickenbach M.; Rutschmann O.; Vernazza P.. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 1998.

Lamivudine for chronic hepatitis B.

Bernasconi E; Battegay M. The New England journal of medicine. 1998.

Relationship between erythema of the proximal nailfold in HIV-infected patients and hepatitis C virus infection.

Courvoisier S; Grob H; Weisser M; Itin PH; Battegay M. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 1998.

[Can HIV/AIDS be healed with new therapies?].

Battegay M. Praxis. 1997.

A specific antibody response to HCV E2 elicited in mice by intramuscular inoculation of plasmid DNA containing coding sequences for E2.

Tedeschi V; Akatsuka T; Shih JW; Battegay M; Feinstone SM. Hepatology (Baltimore, Md.). 1997.

Cytomegalovirus retinitis: Decreased risk of bilaterality with increased use of systemic treatment

Stalder,N; Sudre,P; Olmari,M; Opravil,M; Gabriel,V; Sansonetti,A; vonOverbeck,J; Herbort,CP; Hirschel,B; Battegay,M; Burgisser,P; Jeannerod,L; Egger,M; Erb,P; Fierz,W; Flepp,M; Francioli,P; Grob,P; Gruninger,U; Ledergerber,B; Luthy,R; Malinverni,R; Matter,L; Paccaud,F; Perrin,L; Pichler,W; Rickenbach,M; Rutschmann,O; Vernazza,P. Clinical Infectious Diseases. 1997.

Disseminated Mycobacterium avium complex disease in the Swiss HIV cohort study: Increasing incidence, unchanged prognosis

Low,N; Pfluger,D; Egger,M; Battegay,M; Bernasconi,E; Burgisser,P; Erb,P; Fierz,W; Flepp,M; Francioli,P; Grob,P; Gruninger,U; Hirschel,B; Jeannerod,L; Ledergerber,B; Luthy,R; Malinverni,R; Matter,L; Opravil,M; Paccaud,F; Perrin,L; Pichler,W; Piffaretti,GC; Rickenbach,M; Rutschmann,O; Vernazza,P; vonOverbeck,J. AIDS (London, England). 1997.

Eosinophilia in patients infected with the human immunodeficiency virus.

Tietz A; Sponagel L; Erb P; Bucher H; Battegay M; Zimmerli W. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 1997.

Epidemiologie von Hautkrankheiten bei HIV-Infizierten: Die Basler Kohortenstudie

Itin,P; Schaub,N; Courvoisier,S; Gyr,N; Tietz,A; Rufli,Th; Battegay,M. . 1997.

Hepatitis A virus

Battegay,M; Feinstone,SM. . 1997.

High prevalence and coinfection rate of hepatitis G and C infections in intravenous drug addicts.

Diamantis I; Bassetti S; Erb P; Ladewig D; Gyr K; Battegay M. Journal of hepatology. 1997.

HIV-associated primary pulmonary hypertension - A case control study

Opravil,M; Pechere,M; Speich,R; JollerJemelka,HI; Jenni,R; Russi,EW; Hirschel,B; Luthy,R; Battegay,M; Burgisser,P; Doorly,R; Egger,M; Erb,P; Fierz,W; Flepp,M; Francioli,P; Grob,P; Gruninger,U; Hirschel,B; Ledergerber,B; Luthy,R; Malinverni,R; Matter,L; Opravil,M; Paccaud,F; Perrin,L; Pichler,W; Rickenbach,M; Rutschmann,O; Vernazza,P; vonOverbeck,J. American journal of respiratory and critical care medicine. 1997.

HIV Postexpositionsprophylaxe. Vorläufige Empfehlungen zur HIV-Postexpositionsprophylaxe ausserhalb des Medizinalbereiches

Subkommission; Klinik; (SKK); der; Eidg; Kommission; für; AIDS,Fragen; (EKAF). . 1997.

Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study

Egger,M; Hirschel,B; Francioli,P; Sudre,P; Wirz,M; Flepp,M; Rickenbach,M; Malinverni,R; Vernazza,P; Battegay,M; Bernasconi,E; Burgisser,P; Erb,P; Fierz,W; Grob,P; Gruninger,U; Jeannerod,L; Ledergerber,B; Luthy,R; Matter,L; Opravil,M; Paccaud,F; Perrin,L; Pichler,W; Piffaretti,GC; Rutschmann,O; Zanetti,G. BMJ (Clinical research ed.). 1997.

Influence of hepatitis G virus infection on liver disease.

Diamantis ID; Kouroumalis E; Koulentaki M; Fasler-Kan E; Schmid PA; Hirsch HH; Bühler H; Gyr K; Battegay M. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES. 1997.

Low doses of zidovudine plus didanosine are less effective than higher doses of didanosine monotherapy: a randomized trial in patients pretreated with zidovudine.

Sudre,P; Chave,JP; Ruef,C; Iten,A; Bucher,HC; Vernazza,PL; Furrer,H; Bernasconi,E; Ceserani,N; Battegay,M; Von Overbeck,J; Cassis,I; Lazzarin,A; Gabriel,V; Hirschel,BJ. . 1997.

Neue Empfehlungen zur Behandlung der HIV-Infektion bei Erwachsenen

Subkommission; Klinik; (SKK); der; Eidg; Kommission; für; AIDS,Fragen; (EKAF). . 1997.

Pathogenesis of HCV-infection

Battegay,M. . 1997.

Periungual erythema in HIV-infected patients

Itin,PH; Battegay,M; Gasser,P. . 1997.

Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir

Lorenzi,P; Yerly,S; Abderrakim,K; Fathi,M; Rutschmann,OT; vonOverbeck,J; Leduc,D; Perrin,L; Hirschel,B; Battegay,M; Burgisser,P; Doorly,R; Egger,M; Erb,P; Fierz,W; Flepp,M; Francioli,P; Grob,P; Gruninger,U; Ledergerber,B; Luthy,R; Malinverni,R; Matter,L; Opravil,M; Paccaud,F; Pichler,W; Rickenbach,M; Rutschmann,O; Vernazza,P. AIDS (London, England). 1997.

[Epidemiology of skin diseases in HIV-infected patients: a prospective cohort study].

Schaub N; Gilli L; Rufli T; Gyr N; Battegay M; Nüesch R; Itin P. Praxis. 1996.

[Sex differences in disease course: analysis of the Swiss HIV cohort study].

Schmid M; Twisselmann W; Jacquat BJ; Ledergerber B; Battegay M; Egger M. Schweizerische Medizinische Wochenschrift. 1996.

Antiviral immune responses of mice lacking MHC class II or its associated invariant chain.

Battegay M; Bachmann MF; Burhkart C; Viville S; Benoist C; Mathis D; Hengartner H; Zinkernagel RM. CELLULAR IMMUNOLOGY. 1996.

Erythema of the proximal nailfold in HIV-infected patients.

Itin PH; Gilli L; Nüesch R; Courvoisier S; Battegay M; Rufli T; Gasser P. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY. 1996.

Hepatitis G virus in HCV infected iv drug addicts: High prevalence but no influence on hepatitis outcome

Diamantis,I; Bassetti,S; Erb,P; Ladewig,D; Gyr,K; Battegay,M. Hepatology (Baltimore, Md.). 1996.

Immunity to hepatitis C virus: a further piece of the puzzle.

Battegay M. Hepatology (Baltimore, Md.). 1996.

Infrequent detection of lipoarabinomannan antibodies in human immunodeficiency virus-associated mycobacterial disease

Boggian,K; Fierz,W; Vernazza,PL; Battegay,M; Burgisser,P; Doorly,R; Egger,M; Erb,P; Fierz,W; Flepp,M; Francioli,P; Grob,P; Gruninger,U; Hirschel,B; Ledergerber,B; Luthy,R; Malinverni,R; Matter,L; Opravil,M; Paccaud,F; Perrin,L; Pichler,W; Rickenbach,M; Rutschmann,O; Vernazza,P; vonOverbeck,J. JOURNAL OF CLINICAL MICROBIOLOGY. 1996.

Non-tolerant B cells cause autoimmunity in anti-CD8 IgG2a-transgenic mice.

Battegay M; Fiedler P; Kalinke U; Brombacher F; Zinkernagel RM; Peter HH; Köhler G; Eibel H. EUROPEAN JOURNAL OF IMMUNOLOGY. 1996.

Oral manifestation of disseminated Mycobacterium kansasii infection in a patient with AIDS.

Nüesch R; Battegay M; Zimmerli W; Thumshirn M; Gilli L; Itin PH. Dermatology (Basel, Switzerland). 1996.

Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection

GalettoLacour,A; Yerly,S; Perneger,TV; Baumberger,C; Hirschel,B; Perrin,L; Battegay,M; Burgisser,P; Doorly,R; Egger,M; Erb,P; Fierz,W; Flepp,M; Francioli,P; Grob,P; Gruninger,U; Ledergerber,B; Luthy,R; Malinverni,R; Matter,L; Opravil,M; Paccaud,F; Pichler,W; Rickenbach,M; Rutschmann,O; Vernazza,P; vonOverbeck,J. The Journal of infectious diseases. 1996.

Reasons for failure of prevention of Toxoplasma encephalitis

VanDelden,C; Gabriel,V; Sudre,P; Flepp,M; vonOverbeck,J; Hirschel,B; Battegay,M; Burgisser,P; Doorly,R; Egger,M; Erb,P; Fierz,W; Francioli,P; Grob,P; Gruninger,U; Ledergerber,B; Luthy,R; Malinverni,R; Matter,L; Opravil,M; Paccaud,F; Perrin,L; Pichler,W; Rickenbach,M; Rutschmann,O; Vernazza,P. AIDS (London, England). 1996.

Red fingers syndrome in HIV patients.

Battegay M; Itin PH. Lancet (London, England). 1996.

Richtlinien zur Behandlung der HIV-Infektion mit antiviralen Medikamenten

Subkommission; Klinik; (SKK); der; Eidg; Kommission; für; AIDS,Fragen; (EKAF). . 1996.

Risk factors for tuberculosis among HIV-infected patients in Switzerland

Sudre,P; Hirschel,B; Toscani,L; Ledergerber,B; Rieder,HL; Battegay,M; Erb,P; Malinverni,R; Matter,L; Pichler,WJ; Perrin,L; Frei,P; vonOverbeck,J; Fierz,W; Vernazza,P; Luthy,R; Grob,PJ; Francioli,P; Knopfli,D; Meister,T. The European respiratory journal. 1996.

Use of recombinant protein to identify a motif-negative human cytotoxic T-cell epitope presented by HLA-A2 in the hepatitis C virus NS3 region.

Kurokohchi K; Akatsuka T; Pendleton CD; Takamizawa A; Nishioka M; Battegay M; Feinstone SM; Berzofsky JA. JOURNAL OF VIROLOGY. 1996.

Fibroblasts as efficient antigen-presenting cells in lymphoid organs.

Kündig TM; Bachmann MF; DiPaolo C; Simard JJ; Battegay M; Lother H; Gessner A; Kühlcke K; Ohashi PS; Hengartner H. Science (New York, N.Y.). 1995.

Hepatitis A Virus

Battegay,M; Gust,ID; Feinstone,SM. . 1995.

Neue Empfehlungen zur Behandlung der HIV-Infektion

Subkommission; Klinik; (SKK); der; Eidg; Kommission; für; AIDS,Fragen; (EKAF). . 1995.

Passive Immunotherapie

Subkommission; Klinik; (SKK); der; Eidg; Kommission; für; AIDS,Fragen; (EKAF). . 1995.

Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules.

Battegay M; Fikes J; Di Bisceglie AM; Wentworth PA; Sette A; Celis E; Ching WM; Grakoui A; Rice CM; Kurokohchi K. JOURNAL OF VIROLOGY. 1995.

Role of virus and host variables in virus persistence or immunopathological disease caused by a non-cytolytic virus.

Moskophidis D; Battegay M; van den Broek M; Laine E; Hoffmann-Rohrer U; Zinkernagel RM. JOURNAL OF GENERAL VIROLOGY. 1995.

Saquinavir (Invirase) - Möglichkeiten und Grenzen eines AIDS-Medikamentes

Battegay,M. . 1995.

Suppression of hepatitis C virus (HCV) replication by hepatitis D virus (HDV) in HIV-infected hemophiliacs with chronic hepatitis B and C.

Eyster ME; Sanders JC; Battegay M; Di Bisceglie AM. DIGESTIVE DISEASES AND SCIENCES. 1995.

Elimination of hepatitis delta virus infection after loss of hepatitis B surface antigen in patients with chronic delta hepatitis.

Battegay M; Simpson LH; Hoofnagle JH; Sallie R; Di Bisceglie AM. Journal of medical virology. 1994.

Enhanced establishment of a virus carrier state in adult CD4+ T-cell-deficient mice.

Battegay M; Moskophidis D; Rahemtulla A; Hengartner H; Mak TW; Zinkernagel RM. JOURNAL OF VIROLOGY. 1994.

Hepatitis delta virus RNA in serum of patients with chronic delta hepatitis.

Simpson LH; Battegay M; Hoofnagle JH; Waggoner JG; Di Bisceglie AM. DIGESTIVE DISEASES AND SCIENCES. 1994.

Resistance of lymphocytic choriomeningitis virus to alpha/beta interferon and to gamma interferon.

Moskophidis D; Battegay M; Bruendler MA; Laine E; Gresser I; Zinkernagel RM. JOURNAL OF VIROLOGY. 1994.

Shortcomings of chest radiography in detecting Pneumocystis carinii pneumonia.

Opravil M; Marincek B; Fuchs WA; Weber R; Speich R; Battegay M; Russi EW; Lüthy R. Journal of Acquired Immune Deficiency Syndromes. 1994.

Thymocyte selection and peripheral tolerance using the lymphocytic choriomeningitis virus as a model antigen

Ohashi,PS; Hengartner,H; Battegay,M; Zinkernagel,RM; Pircher,HP. . 1994.

Analysis of neutralizing antibody specificities of different strains of lymphocytic choriomeningitis virus with strain-specific immune sera.

Weibel D; Bründler MA; Zinkernagel RM; Battegay M. RES VIROLOGY. 1993.

Enhancement of disease by neutralizing antiviral antibodies in the absence of primed antiviral cytotoxic T cells.

Battegay M; Kyburz D; Hengartner H; Zinkernagel RM. EUROPEAN JOURNAL OF IMMUNOLOGY. 1993.

Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells.

Battegay M; Moskophidis D; Waldner H; Bründler MA; Fung-Leung WP; Mak TW; Hengartner H; Zinkernagel RM. JOURNAL OF IMMUNOLOGY. 1993.

Lysis of infected cells in vivo by antiviral cytolytic T cells demonstrated by release of cell internal viral proteins.

Kyburz D; Speiser DE; Battegay M; Hengartner H; Zinkernagel RM. EUROPEAN JOURNAL OF IMMUNOLOGY. 1993.

Quantifizierung des Lympho-Choriomeningitis Virus mit einer immunologischen Fokustechnik in 24- oder 96 Lochplatten

Battegay,M. . 1993.

Viruses escaping immunological surveillance

Zinkernagel,RM; Moskophidis,D; Odermatt,B; Schalcher,C; Battegay,M; Kyburz,D; Bründler,M; Ciernik,I; Pircher,HP; Hengartner,H. . 1993.

Vaccination with a synthetic peptide modulates lymphocytic choriomeningitis virus-mediated immunopathology.

Battegay M; Oehen S; Schulz M; Hengartner H; Zinkernagel RM. JOURNAL OF VIROLOGY. 1992.

[HIV infection and syphilis. Case description and literature review].

Steiner A; Battegay M; Greminger P; Lüthy R. Schweizerische Medizinische Wochenschrift. 1991.

Exploring the doctor-patient relationship reduces staff stress and enhances empathy when caring for AIDS patients.

Battegay M; Weber R; Willi J; Eich D; Siegenthaler W; Lüthy R. PSYCHOTHERAPY AND PSYCHOSOMATICS. 1991.

Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates.

Battegay M; Cooper S; Althage A; Bänziger J; Hengartner H; Zinkernagel RM. JOURNAL OF VIROLOGICAL METHODS. 1991.

[Calcium carbonate for the treatment of hyperphosphatemia in chronic hemodialysis patients].

Kiss D; Battegay M; Meier C; Lyrer A. Schweizerische Medizinische Wochenschrift. 1990.

Computergestütztes Monitoring von Antibiotika-Therapien

Blaser,J; Einödter,F; Battegay,M; Ledergerber,B; Lüthy,R. . 1990.

Immunglobuline bei Sepsis und Peritonitis

Battegay,M; Lüthy,R. . 1990.

[Acute digitoxin poisoning].

Battegay M; Cottier C; Burckhardt D; Ritz R. Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis. 1989.

[Endocarditis prevention following rheumatic fever?].

Battegay M; Bonetti A; Lüthy R. Deutsche medizinische Wochenschrift (1946). 1989.

[Pneumothorax as a complication of Pneumocystis carinii pneumonia].

Battegay M; Greminger P; Lüthy R. Deutsche medizinische Wochenschrift (1946). 1989.

Rash with amoxycillin-clavulanate therapy in HIV-infected patients.

Battegay M; Opravil M; Wüthrich B; Lüthy R. Lancet (London, England). 1989.

Mediastinal Hodgkin's disease--a retrospective analysis.

Obrist R; Battegay M; Obrecht JP. ONKOLOGIE. 1988.

[10 years' therapy of Hodgkin's disease in the Oncology Department of the Basel Canton Hospital: a retrospective study].

Battegay M; Obrist R; Obrecht JP. ONKOLOGIE. 1987.

The effect of adrenaline and of alpha- and beta-adrenergic blocking agents on ATP concentration and on incorporation of 32Pi into ATP in rat fat cells.

Stein JM. BIOCHEMICAL PHARMACOLOGY. 1975.

The importance of an innervated and intact antrum and pylorus in preventing postoperative duodenogastric reflux and gastritis.

Keighley MR; Asquith P; Edwards JA; Alexander-Williams J. British Journal of Surgery. 1975.